May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN-1-

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)CONTENTSINVITATION......................................................................................

3

ORGANIZING COMMITTEE ................................................

4

SCIENTIFIC BOARD ..................................................................

4

PROGRAM COMMITTEE .......................................................

4

LOCAL ORGANIZING COMMITTEE .............................

5

GENEROUS SUPPORT ..........................................................

6

ACCESS ...............................................................................................

8

VENUE ..................................................................................................

8

ROOM LOCATION .......................................................................

9

POSTER LAYOUT ......................................................................... 10
MEETING INFORMATION ...................................................... 11
ANCILLARY MEETING .............................................................. 11
SOCIAL PROGRAMS ................................................................ 12
INSTRUCTIONS FOR PRESENTATION ...................... 14
PROGRAM AT A GLANCE .................................................... 16
PROGRAM ......................................................................................... 18
ABSTRACTS .................................................................................... 49
AUTHOR’S INDEX ....................................................................... 245-22 --­­

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANI N V I TAT I O NDear Friends and Colleagues:
It is our great pleasure and honor to welcome you to the 3rd Quadrennial Meetingof the World Federation of Neuro-Oncology (WFNO) to be held jointly with the 6th
Meeting of the Asian Society for Neuro-Oncology (ASNO) in Yokohama, Japan on
May 11-14, 2009.
The World Federation of Neuro-Oncology decided to hold a scientific meetingorganized by three international societies for neuro-oncology, the Society for NeuroOncology (SNO) in U.S.A., the European Association of Neurooncology (EANO) in
Europe, and the Asian Society for Neuro-Oncology (ASNO) in Asia, every 4 years.
The first meeting was held in Washington, DC, U.S.A. in 2001, the second was inEdinburgh, U.K. in 2005, and the third will be hosted by our Asian Society for
Neuro-Oncology in Japan.
We are putting together an attractive program consisting of an educational
symposium on May 11, which will be suitable for post-graduates and those wishing
to learn about updates on recent progress in neuro-oncology. The opening
ceremony followed by a welcome reception will be held in the late afternoon on May
11. The main scientific program will start on May 12 and will include a wide variety
of topics in the fields of diagnosis, treatment, and biology of brain tumors. During
the lunch time, we will prepare “luncheon seminars” to focus on special fields ofneuro-oncology, special techniques for treating patients, or newly developing
treatment modalities.
Yokohama is an international port city next to Tokyo, and it is, therefore, a very
convenient place from Tokyo train station (30min.) and from Tokyo (Narita)
International Airport (90 min.). Yokohama has developed as the base for foreign
trade in Japan since 1859, and it is one of the very few cities in Japan with a diverse
multicultural population with multicultural festivals and events. Yokohama is an ideal
place for exchanging information and ideas freely with your colleagues from all over
the world.
We look forward to meeting you in Yokohama, and to discussing ouraccomplishments and plans for the future of neuro-oncology.
Sincerely,

Masao Matsutani, M.D., D.M.Sci.
President
The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology
and the 6th Meeting of the Asian Society for Neuro-Oncology
Director
Saitama International Medical Center & Comprehensive Cancer Center
Saitama Medical University, Japan-3-

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)■ORGANIZING COMMITTEE
President:
Masao Matsutani (Saitama Medical University International Medical Center, Japan)
Vice President:
Susan Chang (University of California, San Francisco, USA)
Kyung Gi Cho (Azou University, Korea)
Michael Weller (University Hospital Zurich, Switzerland)■SCIENTIFIC BOARD
Susan Chang (University of California, San Francisco, USA)
Jonathan Finlay (Childrens Hospital Los Angeles & University of Southern California, USA)
Abhijit Guha (University of Toronto, Canada)
Erwin van Meir (Emory University School of Medicine, USA)
Michael Vogelbaum (Cleveland Clinic, USA)
Lorenzo M. Bello (University of Milan, Italy)
Beatrice Malmer (Umeå University, Sweden)
Jeremy Rees (Institute of Neurology Queen Square London, UK)
Avelina Tortosa (Universitat de Barcelona, L’Hospitalet de Llobregat, Spain)
Michael Weller (University Hospital Zurich, Switzerland)
Kaya Aksoy (Uludag University, School of Medicine, Turkey)
Kyung Gi Cho (Azou University, Korea)			
Masao Matsutani (Saitama Medical University International Medical Center, Japan)
Shin-Ichi Miyatake (Osaka Medical College, Japan)
Ryo Nishikawa (Saitama Medical University International Medical Center, Japan)
Soichiro Shibui (National Cancer Center, Japan) 		
Tay-Tong Wong (Taipei Veterans General Hospital, Taiwan)		
Liang-Fu Zhou (Shanghai Huashan Hospital, China)■PROGRAM COMMITTEE
Kaya Aksoy (Uludag University, School of Medicine, Turkey)
Lorenzo M. Bello (University of Milan, Italy)
Rolf Bjerkvig (University of Bergen, Norway)
Oliver Bogler (University of Texas MD Anderson Cancer Center, USA)
Eric Bouffet (The Hospital for Sick Children, Canada)
Mitchel Burger (University of California, San Francisco, USA)
Susan Chang (University of California, San Francisco, USA)
Shi-Yuan Cheng (University of Pittsburgh Cancer Institute, USA)
Antonio Chiocca (The Ohio State University Medical Center, USA)
Lisa DeAngelis (Memorial Sloan-Kettering Cancer Center, USA)
Jonathan Finlay (Childrens Hospital Los Angeles & University of Southern California, USA)
Takamitsu Fujimaki (Saitama Medical University, Japan)
Toshihiko Iuchi (Chiba Cancer Center, Japan)
Beatrice Malmer (Umeå University, Sweden)
Shin-Ichi Miyatake (Osaka Medical College, Japan)
Ryo Nishikawa (Saitama Medical University International Medical Center, Japan)-4-May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

Hideho Okada (University of Pittsburgh Cancer Institute, USA)
Stephen Sands (Columbia University Medical Center, USA)
Hideyuki Saya (Institute for Advanced Biosciences, Keio University, Japan)
Yuta Shibamoto (Nagoya City University, Japan)
Soichiro Shibui (National Cancer Center, Japan)
Minoru Suzuki (Kyoto University Research Reactor Institute, Japan)
Jeremy Rees (Institute of Neurology Queen Square London, UK)
Avelina Tortosa (Universitat de Barcelona, L’Hospitalet de Llobregat, Spain)
Erwin van Meir (Emory University School of Medicine, USA)
Michael Vogelbaum (Cleveland Clinic, USA)
Michael Weller (University Hospital Zurich, Switzerland)
Tai-Tong Wong (Taipei Veterans General Hospital, Taiwan)
Takaaki Yanagisawa (Saitama Medical University International Medical Center, Japan)
W. K. Alfred Yung (University of Texas MD Anderson Cancer Center)■LOCAL ORGANIZING COMMITTEE
Norio Arita (Hyogo College of Medicine, Japan)
Akio Asai (Kansai Medical University, Japan)
Takamitsu Fujimaki (Saitama Medical University, Japan)
Takamasa Kayama (Yamagata University, Japan)
Masato Kohchi (Oita San-ai Medical Center, Japan)
Toshihiro Kumabe (Tohoku University, Japan)
Junichi Kuratsu (Kumamoto University, Japan)
Kaoru Kurisu (Hiroshima University, Japan)
Masao Matsutani (Saitama Medical University International Medical Center, Japan)
Shin-Ichi Miyatake (Osaka Medical College, Japan)
Ryo Nishikawa (Saitama Medical University International Medical Center, Japan)
Takanori Ohnishi (Ehime University, Japan)
Yutaka Sawamura (Hokkaido University, Japan)
Hideyuki Saya (Institute for Advanced Biosciences, Keio University, Japan)
Soichiro Shibui (National Cancer Center, Japan)
Kazuhiko Sugiyama (Hiroshima University, Japan)
Jun Takahashi (Kitano Hospital, Japan)
Hideo Takeshima (Miyazaki University, Japan)
Toshihiko Wakabayashi (Nagoya University, Japan)
Jun Yoshida (Nagoya University, Japan)
Toshiki Yoshimine (Osaka University, Japan)
Secretary General
Ryo Nishikawa (Saitama Medical University International Medical Center, Japan)
Secretariat
Takamitsu Fujimaki (Saitama Medical University, Japan)
Takaaki Yanagisawa (Saitama Medical University International Medical Center, Japan)-5-

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)■GENEROUS SUPPORTGenerous support for this Meeting has been provided by the following foundations,associations, societies, companies and hospitals with deepest appreciation.
SPONSORED BY:
Japan Brain Foundation
Pediatric Brain Tumor Foundation
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ)
Nippon Chemiphar Co.,Ltd.
Alfresa Pharma Corporation
Nippon Kayaku Co.,Ltd.
Asahi Kasei Pharma Corporation
Nippon Shinyaku Co.,Ltd.
Aska Pharmaceutical Co.,Ltd.
Nippon Zoki Pharmaceutical Co.,Ltd.
Astellas Pharma Inc.
Nipro Pharma Corporation
AstraZeneca PLC
Novartis Pharma K.K.
Banyu Pharmaceutical Co.,Ltd.
Ono Pharmaceutical Co.,Ltd.
Bayer Yakuhin
Otsuka Pharmaceutical Co.,Ltd.
Bristol-Myers K.K.
Otsuka Pharmaceutical Factory, Inc.
Chugai Pharmaceutical Co.,Ltd.
Pfizer Japan Inc.
Daiichi Sankyo Co.,Ltd.
Rohto Pharmaceutical Co.,Ltd.
Dainippon Sumitomo Pharma Co.,Ltd.
Sanofi-Aventis K.K.
Eiken Chemical Co.,Ltd.
Santen Pharmaceutical Co.,Ltd.
Eisai Co.,Ltd.
Sanwa Kagaku Kenkyusho Co.,Ltd.
Elmed Eisai Co.,Ltd.
Sato Pharmaceutical Co.,Ltd.
Fuso Pharmaceutical Industries, Ltd.
Sawai Pharmaceutical Co.,Ltd.
GlaxoSmithKline K.K.
Schering-Plough K.K.
Japan Tabacco Inc.
Shionogi & Co.,Ltd.
Kaken Pharmaceutical Co.,Ltd.
SSP Co.,Ltd.
Kaken Shoyaku Co.,Ltd.
Taiho Pharmaceutical Co.,Ltd.
Kissei Pharmaceutical Co.,Ltd.
Taisho Pharmaceutical Co.,Ltd.
Kowa Shinyaku Co.,Ltd.
Takeda Bio Development Center Limited.
Kracie Holdings,Ltd.
Takeda Pharmaceutical Co.,Ltd.
Kyorin Pharmaceutical Co.,Ltd.
Teijin Pharma Limited
Kyowa Hakko Kirin Co.,Ltd.
Terumo Corporation
Maruho Co.,Ltd.
Maruishi Pharmaceutical. Co.,Ltd.
Toa Eiyo Pharmaceutical Company
Torii Pharmaceutical Co.,Ltd.
Meiji Seika Kaisha Ltd.
Towa Pharmaceutical Co.,Ltd.
Minophagen Pharmaceutical Co.,Ltd.
Toyama Chemical Co.,Ltd.
Mitsubishi Tanabe Pharma Corporation
Tsumura & Co.
Mochida Pharmaceutical Co.,Ltd.
Wakamoto Pharmaceutical Co.,Ltd.
Mylan Inc.
Wyeth Lederle Japan,Ltd.
Nihon Pharmaceutical Co.,Ltd.
Yakult Honsha Co.,Ltd.
Nippon Boehringer Ingelheim Co.,Ltd.
Others:Asamoto Clinic
Bishinkai Kurosawa Hospital
Hannou Seiwa Hospital
Harada Clinic
Helios Society Hospital
Keijinkai Hospital
Kitamura Neurosurgery Clinic
Matsumiya Noshinkeigeka Clinic
Minamisunamachi Clinic
Mitaka Nakamura Noshinkeigeka Clinic
Moriyama Memorial Hospital

Motobu Noge Hospital
Nagashima Nogeka Clinic
Nakamura Memorial Hospital
Obitsu Sankei Hospital
Ohbayashi Clinic
Ohkawara Neurosurgical Hospital
Sougo Minami-Tohoku Hospital
Suzuki Neurosurgical Clinic
Yamamoto Maeda Memorial Hospital
Yoseikai Teraoka Memorial Hospital-6-

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANSUPPORTED BY:
American Family Life Assurance Company of Columbus
Ark Therapeutics Ltd.
Carl Zeiss Meditec Co., Ltd.
Chugai Pharmaceutical Co.,Ltd.
Daiichi-Sankyo Co., Ltd.
Eisai Co., Ltd.
Fujita Medical Instruments Co., Ltd.
Johnson & Johnson K.K.
Merck Serono
Mitsubishi Tanabe Pharma Corporation
NAKANISHI INC.
NovoCure Ltd.
ONO & CO.,LTD.
Olympus Medical Systems Corp.
SBI ALA PROMO Co., Ltd.
Schering-Plough
Specified Nonprofit Corporation Gold Ribbon Network
Toray Medical Co., Ltd.

EXHIBITORS:
Ark Therapeutics Ltd.
Cell-Medicine, Inc.
Children’s Cancer Association of Japan (CCAJ)
Elekta K.K.
International Brain Tumour Alliance (IBTA)
Leica Microsystems K.K.
Medical Publisher Service
Merck Serono
ONO & CO.,LTD.
Pediatric Brain Tumor Foundation
Schering-Plough
Society for Neuro-Oncology

Specified Nonprofit Corporation Gold Ribbon Network
Yoshida Manufacturing Co., Ltd.

(in alphabetical order)
as of April 24, 2009-7-

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)■ACCESS*Tokyu Toyoko Line is connected directly to Minato Mirai Line.

■Venue
PACIFICO YOKOHAMA
1-1-1, Minato Mirai, Nishi-ku, Yokohama, 220-0012 Japan
TEL:+81-45-221-2155 (General Information)
URL: http://www.pacifico.co.jp/english/index.html-8-

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN■ROOM LOCATION

1F
Congress Bag

▶

122
121

123

Cloak

Main Hall▶

Room 1

125

124

PC Preview Center

1F

▶

2F
221

Registration Desk
Information Board

222

▶
▶

225

Travel Desk

▶

223
224

226

211

212

2F

Lounge▶

May 11
Welcome Reception

May 14
Japanese Culture
ProgramPoster Viewing 3▶

3F

May 12
Hands-on Seminar▶

Poster Viewing 2▶

Poster Viewing 4▶

PosterViewing 1&
Exhibition

Room 2

May 11
Educational Seminar(303+304)▶

▶

Book Display and Sale

Room 3▶
▶

Poster Registration

Secretariat-9-❋Room 301, 302, Foyer = Internet access is available.

3
3

3
3

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with3The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)
3

3

■POSTER LAYOUT







3

 




3
3


3
3



3
3

PosterViewing 3

3

3
3

3
3

3
3

3

3
3

3

s

3F

3

3

3
3

3
3

3
3

3
3
3

3
3

3
3

3
3
3
3
3
3
3

3
3
3
3
3
3
3

PosterViewing 1

3

3

3

3
3

3

3
3
3

3
3
3
3
3
3
3
3
3

3

3
3
3

3
3



3

3
3

Poster Viewing 4

PosterViewing 2

3
3

3
3
3

3
3
3
3
3
3
3
3
3

s

3
3
3
3



3
3

s

3
3



3
3

3

3
3

PosterRegistration



 





3

Program
Stem Cell Science
Surgery for Malignant Glioma
Immunology
Gene Therapy
Pediatric Neuro-Oncology I
Hoshino Award Selection
Basic Science I, Genome - Proteome
Stem Cell Science Posters
Diagnostic Radiology
Novel Treatment Approach
GliomaMetastatic Brain Tumors
Epidemiology
Poster Presentations: Neurosurgery
Poster Presentations: Neurosurgery
Temozolomide and MGMT
Angiogenesis and Anti-Angiogenesis Therapy
Chemothrapy, Molecular-Targeted Therapy
Pediatric Basic Science I
Cognitive Function and Outcome
Poster Presentations: Basic Science
Poster Presentations: Basic Science
Radiation Oncology
Primary Central Nervous System Lymphoma- 10 -

Poster Number
P001−P006

P007−P022
P023−P025
P026−P027
P028−P040
P041−P067
P068−P076
P077−P088

P089−P102
P103−P105

P106−P113
P114−P119
P120
P121−P126
P127−P167
P168−P179
P180−P184
P185−P214
P215−P220
P221−P224
P225−P252
P253−P294
P295−P311
P312−P318

Area


 





Poster Viewing 1
Room 301+302

3
3
3
3
3
3
3
3
3



3
3
3
3
3
3
3
3
3

3
3

3
3

3

3
3
3
3
3
3
3

Poster Viewing 23
3
Room 311+312 3
3
3
3

Poster Viewing 3
Room 313+314
Poster Viewing 4
Foyer

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN■MEETING INFORMTAION●Registration Desk
The Registration Desk is located on the 2nd floor of the PACIFICO YOKOHAMA.
The Registration Desk will open at the following times:
May 10 (Sun)15:00-18:00

May 11 (Mon) 10:00-21:00
May 12 (Tue)

07:30-18:00

May 13 (Wed) 07:30-18:30
May 14 (Thu)

07:30-18:00● Travel Desk
The Travel Desk will be located next to the Registration Desk to assist you with anytransportation questions you might have. Also, if you are interested in sightseeing information,changing flight departure dates or general travel information, please direct your inquiries to
the Travel Desk.
● Name Tags
Name Tags are mandatory for access to all Scientific Sessions, the Commercial Exhibits andSocial Programs.
- Accompanying persons will not be allowed in the Scientific Sessions.
- Exhibitors will not be allowed except in Exhibition unless you have paid the Meeting
registration fee.
- Seminar/Symposium sponsors will not be allowed except in your own sponsoredprograms unless you have paid the Meeting registration fee.
- Access to all programs will be strictly controlled; therefore, please wear your Meeting
Name Tags at all times.
●Internet AccessInternet access is available during this meeting. It is located on the 3rd floor in the lobby andExhibition areas.
●Secretariat OfficeWill open during this meeting 3F, Room 315
Tel: 045-228-6392●Hands-On Seminar
Date: Tuesday, May 12
Time: 11:00-13:00
Venue: 3F, Lounge, PACIFICO YOKOHAMA
Registration: May 11 (Mon) 10:00-21:00, Registration Desk (2F)
May 12 (Tue) 07:30-10:00, Registration Desk (2F)
10:00-11:00, In front of the Lounge (3F)
Limited number of attendance: 80 people
Note: 32 people will be able to have experience in operations on who registered on a first-come, first-served basis.

●Safety and Security
Please do not leave bags unattended at any time, whether inside or outside session. Hotels
strongly recommend that you use their safety deposit boxes for your valuables.

■ANCILLARY MEETING
May 11 (Mon)
ASNO Business Meeting (invited members only)
Time: 13:00-14:00
Venue: 2F, Room 211 + 212, PACIFICO YOKOHAMA- 11 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)■SOCIAL PROGRAMS●Opening Ceremony
Date: May 11 (Mon)Time: 18:00-18:30
Venue: 1F, Main Hall, PACIFICO YOKOHAMA
Fee:
Free
● Charity Concert
Date: May 11 (Mon)Time: 18:30-19:30
Venue: 1F, Main Hall, PACIFICO YOKOHAMA
Special notes: 1. The concert will be open to the public. Hence, there will be a limited number of seats available due		 to selling tickets at a price of JPY2,000 on a first-come-first served basis on that day.
2. The proceeds from the concert will be donated to Children’s Cancer Association of Japan (CCAJ) and		 to Pediatric Brain Tumor Foundation (PBTF) in the USA.

●Welcome Reception
Date: May 11 (Mon)Time: 19:40-21:30
Venue: 3F, Lounge, PACIFICO YOKOHAMA
Fee:
Free (included in the registration fee)
● Meeting Dinner
Date: May 12 (Tue)
Time: 19:00-21:00
Venue: 3F, Ball Room, InterContinental Yokohama Grand
Fee:
Free (included in the registration fee)
● Banquet
Date: May 13 (Wed)
Time: 19:00-21:00
Venue: B2, Ball Room, Pan Pacific Yokohama Bay Hotel Tokyu
Menu: French cuisine (macrobiotic food carefully selected ingredients by Grand Chef
Toshinori Sogabe)Fee:¥10,000●Accompanying Persons’ Programs
Optional Sightseeing Tour and Culture Program
Wednesday, May 13
Time:
Price:

09:00-16:30¥12,000 per person
Sightseeing tour to Kamakura, the ancient capital city of Japan, to visit The Great
Image of Buddha (Daibutsu), designated as a National Treasure.

Thursday, May 14
Culture program/demonstration which you can enjoy a hands-on experience of Japanese culture.
Time: 10:00-17:00
Venue: 3F, Lounge, PACIFICO YOKOHAMA
Price: Free
Program/demonstration:
You can take your work home as a souvenir
1. Origami (the traditional Japanese art of paper folding)
2. Japanese Calligraphy (the art of Japanese words)
3. Nigaoe (have your portrait sketched)
4. NioiBukuro (making fragrance bags, made of the material of the kimono)- 12 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN◆ Post Meeting TourFor details and applications, ask at the Travel Desk
Friday, May 15
Time:
Price:

07:30-17:00¥13,000 per person
Sightseeing tour to Mount Fuji 5th Station
Enjoy a bus tour to the fifth station of Mt. Fuji and experience the beautiful view
from the 5th station.

Notes: 1. This tour will take you to the 5 th station of Mt. Fuji not to the summit. It is officially open for climbing only during
summer from July to September, where Mount Fuji (Fujisan) is Japan’s highest mountain at 3,776 meters.
2. Tour may be cancelled when the participants are under 20 persons.

●Hoshino Award Selection and Ceremony
Presentation by selected candidates
May 13 (Wed) 08:00-09:30
Venue: 1F, Main Hall, Room 1
Selection of Winners and Announcement
May 13 (Wed) 14:00
The winners will be posted on the board at the Poster Registration on the 3rd Floor andcongratulated ribbons are put on the winners’ posters.
Award Ceremony
May 13 (Wed) 18:30-18:45
Venue: 1F, Main Hall, Room 1
Personal History of Dr. Hoshino
Professor Takao Hoshino was the pioneer of cell kinetics of brain tumor. He continued his work on brain tumor research until
he passed away from gastric cancer at the age of 55.
He is one of the founding members of the Japan Society for Neuro-oncology together with Professor Masakatsu Nagai,
which later became one of the cores of the Asian Society for Neuro-oncology (ASNO).
He was born and grown up in Tokyo, graduated from the University of Tokyo in 1962 to get M.D. He started his carrier as aneurosurgeon to join the Department of Neurosurgery just founded by Professor Keiji Sano. The Department was the first
Neurosurgical Department in Japan and he is the “firstborn” to Professor Keiji Sano. In 1964, during his stay in Israel, heencountered with a molecule called bromodeoxyuridine (BrdU, BUdR) which is an analogue of thymidine. He found that thismolecule has a radiosensitized effect on cells and he invented a new therapy called BAR therapy of malignant brain tumors.
BrdU, which was injected into the carotid artery was incorporated into the nuclei of the tumor cells during their DNA
synthesis. During irradiation therapy, this incorporated BrdU works as a radiosensitzer to the tumor cells. With this therapy anumber of patients with malignant brain tumor survived better. Although the treatment did not spread widely because of thelimitation of technology, i.e. catheter or infusion pump of that time, the concept per se was a really an innovative one.
Dr. Hoshino got his D.M.Sc. in 1973 from the University of Tokyo and soon became research fellow at the University ofCalifornia, San Francisco for three years. After his stay in the USCF, he occasionally got faculty positions in the University ofTokyo or Tokyo Metropolitan Komagome Hospital, but mostly stayed in the faculty position in USCF. He finally leaded theBrain Tumor Research Center of USCF as a full professor until he came back to Japan as a Professor in Neuro-oncology,
Kyorin University in 1989.
During his research work, he realized that brain tumor cells are not just stay on glass slide as “pathology specimens” but they
are dynamic biological phenomena in human body. He tried to analyze the movement of cells or “cell kinetics” of tumor cells
initially labeling S-phase cells by tritiated thymidine, by which we can tell which cells are dividing cells under microscope.
Interestingly, in this cell kinetics field, the molecule BrdU re-appeared on-stage in 1980th. The technique of monoclonal
antibody was invented and anti-BrdU monoclonal antibody was available now. He injected BrdU before removal of themalignant tumors, then stained the surgical specimen with anti-BrdU monoclonal antibody to detect the dividing cells. His 10
years research in this field yielded vast knowledge on dynamics or cell kinetics of malignant brain tumors, especially gliomas.
Since his work on neuro-oncology was so wide, it is difficult to mention all of them in a limited space. It is for sure that withhis work, the brain tumor became a dynamic vivid existence from static phenomenon under glass slides. With theseadvancement of knowledge of brain tumors, the treatment strategy to brain tumors has been advanced remarkably.
He had been a good friend of Professor Charles B. Wilson, the former Chairman of the Department of Neurosurgery, UCSF
and also of Professor Victor Levin of Neurooncology, UCSF and MD Anderson Cancer Center. He trained many neurooncologists around the world including many Asian exchange scientists. Professor Masao Matsutani was also influenced a
lot from Dr. Hoshino when Masao was junior to Takao at Tokyo Metropolitan Komagome Hospital.
Dr. Hoshino served as an editor or a reviewer for many academic journals including Journal of Neuro-oncology, Cancer Research,
Journal of Neurosurgery, Neurosurgery and so on. He published more than 197 articles in various academic journals.
He was awarded with Anne and Jason Farber Award from the American Academy of Neurology 1990 for his long-lasting
outstanding contribution in neuro-oncology field.
Although he was diagnosed to have advanced gastric caner on 1987, his enthusiasm for research never faded away until hislast day. He endured two surgeries and many hard chemotherapy protocols, without stopping his research carrier. He
served as a president for the Annual Meeting of the Japan Society for Neuro-oncology in November 1992. During themeeting, although he was wearing a jacket for central venous line, he made many comments and questions with his usual
piercing eyes. However the final day came at last and he passed away January 28th, 1993.
To memorize his achievements in neuro-oncology and to encourage young investigators, a fund was established andHoshino Award was given to young investigators every year at the Japan Society for Neuro-oncology since 1993.

- 13 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)■ INSTRUCTIONS FOR PRESENTATION
I. Disclosure of Conflicts of Interest
The 3rd WFNO/the 6th ASNO is committed to ensuring the integrity of its scientific,
educational, and research programs and offering the best continuing medical educationin neuro-oncology. Disclosure of conflicts of interest helps maintain the integrity of theinformation presented at the 2009 WFNO/ASNO meeting. To help support this effort,
WFNO/ASNO requires that all meeting presenters honor the WFNO/ASNO Conflict-ofInterest Policy. This policy requires disclosure of any financial or other interest that might beconstrued as resulting in an actual, potential, or apparent conflict.
Additionally, WFNO/ASNO abides by rules formulated by the Accreditation Council for
Continuing Medical Education (ACCME), which require presenters to disclose possible
conflicts both verbally and in writing. As a presenter, this means you must disclose any
relevant financial relationships you or your spouse/partner has had within the past 12
months. For this purpose, “relevant financial relationships” are those from which you or your
spouse/partner have received or may received financial benefit and which are related toannual meeting CME content.
By submitting a disclosure, you agree that you have read WFNO/ASNO Conflict-ofInterest Policy and understand and support its intent. To ensure full disclosure and proper
preparation of your presentation, please review the following information according to yourpresentation format (PowerPoint or Poster).
PowerPoint Presentations
WFNO/ASNO rules session chairs and speakers to include conflict-of-interest disclosureslides in their presentations and inform audiences of any conflicts verbally. In addition,
WFNO/ASNO requires its faculty to disclose to the audience any discussion of off-label
use of a drug or medical device in their presentation. This promotes transparency andunderstanding in practice. If these requirements are not met, the presentation may bestricken from the program.
When preparing your PowerPoint presentation, be sure to include a disclosure slide
immediately after your title slide. If you have nothing to disclose, a statement to that effect,“There are no relevant conflicts of interest to disclose,” should be included on the slides
and stated in your presentation, consisting of 1st slide: Title; 2nd slide: Conflict-of-interest
disclosure slide; 3rd slides ～ Presentation contents.
Poster PresentationsFirst authors must list conflicts of interest for themselves and all co-authors on the bottomsof the poster.
If an author has nothing to disclose, his or her statement should read, “I have not relevant
conflicts of interest to disclose.” If none of the authors of the absence have relevant
conflicts of interest to disclose, the statement should read, “There are no relevant conflictsof interest to disclose,” to be followed in the same manner as described above.

II. Instructions for ORAL Presentation
Clarity of slides is vital for a successful scientific presentation.
1. All the speakers are requested to keep to the time previously allotted for each.
Green and Orange lamps will tell you how much time is remaining in your presentation.
A green lamp will indicate when one minute remains, while an orange will light up whenno time remains.
2. All presentations will be done on PC.
3. Please bring your own PC and a backup of your data.
The only PC media that will be available are CD-R, DVD-R, or USB.
4. PCs with Windows XP and PowerPoint 2003 are to be used.
PCs with Macintosh OS X and PowerPoint 2004 are to be used.
Windows Vista/Macintosh users: Please bring your own computer for your presentation.
5. Animation and sound functions will be available. If your presentation data is in PC media,
please make sure that the data is compatible with Media Players for Windows or Quick
Time for Macintosh. Standard PC fonts (for Windows or Macintosh) should be used.
- 14 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN6. If you are using your own PC, please make sure to bring an AC
adaptor (standard
2-pin type). For projector output purposes, a VGA cable will
be provided. Please confirm whether your PC is equipped withan RGB jack (mini D-sub 15 pin type) as standard. If you use
a different type of RGB jack to connect to an external monitor,
please bring it with you. XGA (1024x768) is the suitable monitor
size. For purpose data projection, please adjust your screen
setting to XGA. Please cancel your screen saver and power saving settings in advance,
especially if your data includes video image and sound.
7. Please bring your PC or PC data to the PC Preview Center located in the 1F Lobby atleast 30 minutes prior to your presentation to register and submit it to test the connection
and view your file. If you are delayed, we will inform the chairperson of your session who
will postpone your presentation for a few minutes if necessary.
8. Those who bring your PPT presentation on CD-R, DVD-R, or USB, after you havechecked your data; please bring it to the Presentation Room by yourself for data
backups.
Those who bring your own PC, after you have checked your data, please bring it to the
Operation Desk located in front of the Presentation Room. After your presentation, yourPC will be back to you.
9. Please use the mouse and keyboard on the podium for your presentation. You arerequired to handle your data yourself, using the mouse and keyboard connected to thePC.
10. The copied data for your presentation will be deleted by the secretariat after the meeting.

III. Instructions for POSTER Presentation
Presenters should prepare four (4) slides for platformpresentation in addition to the conflict-of-interest disclosureslide and poster.
1. PosterPresenters are requested to follow the schedule below
when mounting your poster on the assigned board andremoving your poster materials from the board.

90cm
70cm

20cm

Presentation Title
Affiliation
Author's Name

20cm

Presentation No.

Set-up:May 12 07:30-12:00
Remove: May 14 17:00-18:00
Posters: 90cm wide x 180cm high160cm

Your poster presentation number will be posted on yourassigned board.
Posters are still mounted after 18:00, these will be deleted
by the Secretariat.
2. Platform Presentation
Please prepare 5 slides for platform presentation as described below. The presentation
will be allocated a 3-minute time slot. Presentations are conducted in the Platform
Presentation Room.
1 st slide:

Title slide

2 nd slide:

Conflict-of-interest disclosure slide

3 rd – 5th slides: Presentation contents
Please refer to the section ( I ) above for the poster creation method.

- 15 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)■ PROGRAM AT A GLANCE
May 11 (Mon) Previous Day
Lobby (2F)
7:00
8:45
8:00
9:15
9:00

Room 1Main Hall (1F)

Room 2303 (3F)

10:00
10:15
11:00
11:15
12:00

Room 3304 (3F)

Lounge (3F)

Poster Viewing & Exhibition

301+302 (3F)

Registration

13:00
Educational
Lectures

14:00
15:00
16:00

Registration

17:00
18:00
Opening Ceremony
Charity Concert

19:00
20:00

Welcome
Reception

21:00

May 12 (Tue) 1st Day
Lobby (2F)
7:00
8:45
8:00
9:15
9:00
10:00
10:15
11:00
11:15
12:00
Registration
13:00
14:00
15:00
16:00
17:00

Room 1Main Hall (1F)

Room 2303 (3F)

Stem Cell Science

Surgery for Malignant
GliomaInvited Lecture

Special Seminar

Lunchtime Seminar
Role of Surgery in The
Treatment of
Malignant Brain
Tumors
Evening Symposium

Room 3304 (3F)

Lunchtime Symposium

Invited Lecture
Lectures Open to the
PublicGene Therapy

18:00
19:00
20:00

Meeting Dinner at InterContinental Yokohama Grand

21:00- 16 -

Poster Viewing & Exhibition

301+302 (3F)

Pediatric
Neuro-Oncology I

Lunchtime Symposium

Immunology

Lounge (3F)

Hands-On
Seminar
Skull Base
Technique

PosterViewing &Exhibition

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANMay 13 (Wed) 2nd day
Lobby (2F)
7:00
8:45
8:00
9:15
9:00

Hoshino Award
Selection

Lecture from SNO
Registration

Room 2303 (3F)

Diagnostic Radiology

Basic Science I,
Genome-Proteome

10:00
10:15
11:00
11:15
12:00
13:00

Room 1Main Hall (1F)

Lunchtime Seminar

Ongoing Clinical Trials
and the Future Directionof Glioma Treatment

15:00
16:00
17:00

Novel Treatment
Approach
Lunchtime Seminar

Poster Viewing & Exhibition

301+302 (3F)

GliomaStrategies forManagement of Patientswith Brain Tumors in
Emerging Countries

PosterViewing&
Exhibition

Epidemiology
Sellar/Parasellar
Lesions
Meningnioma, Chordoma

Basic Science II
Poster Presentations,
Neurosurgery

Special Lecture

18:00

Lounge (3F)

Metastatic Brain Tumors

Lecture from EANO

14:00

Room 3304 (3F)

Stem Cell Science Posters
Hoshino Award Ceremony

19:00

Banquet at Pan Pacific Yokohama Bay Hotel Tokyu

20:00
21:00

May 14 (Thu) 3rd Day
Lobby (2F)
7:00
8:45
8:00
9:15
9:00
10:00
10:15
11:00
11:15
12:00
13:00

Room 1Main Hall (1F)

Room 2303 (3F)

Temozolomide and
MGMT

Pediatric Basic
Science I

Angiogenesis andAnti-Angiogenesis
Therapy

Pediatric
Neuro-Oncology II

16:00

Registration

Lunchtime Symposium

Lunchtime Seminar
Cognitive Function
and Outcome

Chemotherapy,
Molecular-Targeted
Therapy

Pediatric Basic
Science II

17:00
18:00

Lounge (3F)

Closing Ceremony

19:00
20:00
21:00

- 17 -

Poster Viewing & Exhibition

301+302 (3F)

Poster Presentations:
Basic Science

Lecture from ASNO

14:00
15:00

Room 3304 (3F)

Lunchtime Symposium

Radiation Oncology

Primary Central
Nervous System
LymphomaJapanese
CultureProgramPosterViewing&
Exhibition

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)■PROGRAMMay 11 (Mon) 303+304 *previous day
lEducational Lectures: Treatment of Malignant Brain Tumors
Chairperson: Takamitsu Fujimaki (Japan)

Introduction
11:00 		GERM CELL TUMOR 				

Takamitsu Fujimaki (Japan)

11:20				

PEDIATRIC BRAIN TUMOR (MEDULLOBLASTOMA, EPENDYMOMA, CHOROID PLEXUS PAPILLOMA)
Mark W. Kieran (USA)11:50				

Irene Slavc (Austria)

PREVENTION AND/ OR MANAGEMENT OF ADVERSE EVENTS, SUPPORTIVE CARE––––––––––––––––––––––––– Lunch –––––––––––––––––––––––––

Chairpersons: Susan Chi (USA)		
Yasushi Ino (Japan)

13:05				

Andreas von Deimling (Germany)

LECTURE ON NEUROPATHOLOGY

13:35 				Koichi Ichimura (UK)14:00 				Sarah Nelson (USA)14:25 				Mark R. Gilbert (USA)

14:50 				Susan Chang (USA)

MOLECULAR PATHOGENESISNEUROIMAGING (PET, MRI)GLIOBLASTOMALOW GRADE DIFFUSE ASTROCYTOMA––––––––––––––––––––––––– Break –––––––––––––––––––––––––OLIGODENDROGLIOMA

15:25 				Keisuke Ueki (Japan)

15:45 				Gabriele Schackert (Germany)

16:10 				NEW AGENTS, MOLECULAR TARGETING THERAPY
Clifford Schold (USA)16:30				

Antonio Omuro (USA)METASTATIC BRAIN TUMORPRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

May 11 (Mon)18:00 		18:30 		19:40 		Room 1

Opening Ceremony
Charity Concert
Welcome Reception (3F, Lounge)

May 12 (Tue)Room 1lStem Cell Science
Chairpersons: Sin-Soo Jeun (Korea)		
Manfred Westphal (Germany)

08:00 P001
		
08:03 P002
		

CD133: STILL A MARKER OF BRAIN TUMOR STEM CELLS?

Xuqun Tang (China)

CD133 NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE MARKERS 		DISPLAY TUMORGENICITY IN VIVO.
Per Oyvind Enger (Norway)- 18 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

08:06 P003
		

08:09 P004
		

08:12 P005
		

08:15 P006
		

08:25 O001

NOVEL TECHNIQUE FOR ESTABLISHMENT OF GLIOBLASTOMA STEM CELL LINE AND PATHOLOGICALVERIFICATION OF DISTRIBUTION AND DIFFERENTIATION STAGE OF TUMOR CELLS ON ITS XENOGRAFT.
Koichi Yoshikawa (Japan)
THERAPEUTIC EFFECT OF GENETICALLY ENGINEERED MESENCHYMAL STEM CELLS IN RAT
EXPERIMENTAL LEPTOMENINGEAL GLIOMA MODEL
Chunyu Gu (Japan)
CHLOROQUINE SUPPRESSES GLIOMA CELL VIABILITY AND SENSITIZES RADIORESISTANT STEM-LIKE
GLIOMA CELLS TO IONIZING RADIATION AND CHEMOTHERAPYElla L. Kim (Germany)
ESTABLISHMENT AND CHARACTERIZATION OF AN EXPERIMENTAL MODEL OF INVASIVE GLIOMA WITHHIGHLY RADIORESISTANT PHENOTYPE.
Ella L. Kim (Germany)		

NG2 EXPRESSION ESTABLISHES A LINK BETWEEN NEURAL PRECURSORS AND CANCER STEM CELLSIN GLIOBLASTOMA
Talal M. Fael Al-Mayhami (UK)

08:55 O002		Akio Soeda (USA)

09:05 O003
		

Hideyuki Saya (Japan)

09:15 O004
		
09:25 O005

A SINGLE CD133-POSITIVE CELL IS CAPABLE OF PRODUCING GLIOMA POPULATION DIVERSITYANALYSIS OF CANCER STEM CELLS IN GENETICALLY-INDUCED BRAIN TUMORSGLIOMA STEM CELLS ARE INVOLVED IN TUMOR TISSUE REMODELING IN XENOGRAFT MODEL

Jun Dong (China)		

ENDOTHELIAL CELLS AND DIFFERENTIATED TUMOR CELLS FUNCTION AS A STEM NICHE TOGLIOBLASTOMA STEM-LIKE CELLS BY PROVIDING NOTCH LIGANDS
Xing Fan (USA)09:35 O006
		

Do-Hyun Nam (Korea)

09:45 O007
		

Deepak Kamnasaran (Canada)

09:55 O008
		

10:05 O009
		

10:15 O010
		

10:25 O011
		

10:35 O012
		

AN ESSENTIAL ROLE OF C-MET/HGF SIGNALING IN GLIOBLASTOMA INITIATING CELLSDEVELOPMENT AND APPLICATIONS OF STEM CELL BASED PRE-CLINICAL MODELS OF GLIOMASIN VIVO TRACKING SPIO LABELLED MESENCHYMAL STEM CELL TROPISM TOIN VIVO TRACKING
NANOPARTICLE-LABELLED STEM CELL TROPISM TO BRAIN MALIGNANT GLIOMA AFTERSYSTEMATICAL INJECTION BY A CLINICAL 1.5T MR
Jianhong Zhu (China)
P53 INDEPENDENT ABROGATION OF G1 ARREST IN MURINE BRAIN TUMOR-DERIVED STEM LIKECELLS AFTER IONIZING RADIATION
Cynthia Wetmore (USA)ANGIOGENESIS OF GLIOMAS: VASCULAR TUBE FORMATION FROM TRANSDIFFERENTIATION OF
GLIOMA STEM/PROGENITOR CELLS.
Qiang Huang (China)
DUAL-TARGETED ANTITUMOR EFFECTS AGAINST BRAINSTEM GLIOMA BY INTRAVENOUS DELIVERY OF
TRAIL GENE TRANSFERED STEM CELLS
Jian-Hong Zhu (China)
ALTERED EXPRESSION OF MICRORNA CLUSTERS IS ASSOCIATED WITH THE STEMNESS PROFILE OF GLIOMASIris Lavon (Israel)lInvited Lecture
Chairperson: Hideyuki Saya (Japan)

11:00 IL01
		

STEM CELLS AND CANCER STEM CELLS

Toshio Suda (Japan)

lLunchtime Seminar: High Grade Glioma: The Emergence of Gene Medicines
Sponsored by Ark Therapeutics Ltd.

Chairperson: Manfred Westphal (Germany)

12:00 LSe01
		
12:30 LSe02
		

GENE MEDICINES FOR THE TREATMENT OF HGG

Zvi Ram (Israel)

SITIMAGENE CERADENOVEC: PHASE III CLINICAL TRIAL RESULTS

Manfred Westphal (Germany)- 19 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

lRole of Surgery in The Treatment of Malignant Brain Tumors
Sponsored by Johnson & Johnson K.K.

Chairpersons: Lorenzo M. Bello (Italia)
		
Kyung Gi Cho (Korea)
		
Yuanli Zhao (China)

13:00 O013
		Mark M. Souweidane (USA)

13:30 O014
		

Gabriele Schackert (Germany)

14:00 O015
		
14:30 O016
		

THE ROLE OF SURGERY IN THE MANAGEMENT OF PEDIATRIC BRAIN TUMORSSURGERY OF SUPRATENTORIAL PEDIATRIC BRAIN TUMORSSURGICAL RESECTION STRATEGIES FOR OPTIMIZING GLIOMA REMOVAL

Mitchel S. Berger (USA)GLIOMA SURGERY, ITS ADVANCEMENTS, PROBLEMS AND FUTURE

Takamasa Kayama (Japan)

lEvening Symposium: Temozolomide, New Aspects
Sponsored by Schering-Plough

Chairperson: W.K. Alfred Yung (USA)

15:10 ES01

Molecular characteristic of LGG

W.K. Alfred Yung (USA)

15:40 ES02
		Martin van den Bent (Netherlands)

16:10 ES03
		Toshihiro Kumabe (Japan)

16:40 ES04
		

Michael Prados (USA)

Prognosis and the role imaging in prognostic prediction in LGG
When to decide resection in LGG
Role of chemotherapy in management of LGG

May 12 (Tue)Room 2

lSurgery for Malignant Glioma
Chairpersons: Chun Kee Chung (Korea)
		Christianto Lumenta (Germany)		Keisuke Ueki (Japan)		

08:00 P007

FUNCTIONAL RESULTS AFTER RESECTION OF GLIOMA INVOLVING THE SUPPLEMENTARY MOTOR AREA
Takeo Uzuka (Japan)

08:03 P008
		

Yoshiki Arakawa (Japan)

08:06 P009
		

Mikhail Chernov (Japan)

08:09 P010
		

Satoshi Horiguchi (Japan)

08:12 P011

THE DIAGNOSTIC IMPACT OF RADICAL RESECTION IN THE MANAGEMENT OF LOW-GRADE GLIOMAEXPERIENCE WITH SPECTROSCOPY-SUPPORTED STEREOTACTIC BRAIN BIOPSYUSEFULNESS OF FDG-PET-CT-GUIDED STEREOTACTIC BIOPSY FOR BRAIN TUMORS		NEURONAVIGATION AND BRAIN BIOPSY. SURGICAL TECHNIQUE AND COMPARISON WITH TRADITIONALESTEREOTAXIC METHOD.
Jesus Merino (Spain)

08:15 P012
		

Chi-tun Tang (Taiwan)

08:18 P013
		

Seung Hwan Lee (Korea)

08:21 P014

THE ROLE OF DIFFUSION TENSOR IMAGE OF THE TUMOR RESECTION
USEFULNESS OF FIBER TRACT NAVIGATION IN TUMOR SURGERY ADJACENT TO ELOQUENT AREA		

PREOPERATIVE FUNCTIONAL IMAGING AND INTRAOPERATIVE MONITORING FOR IMPROVINGRESECTION RATE OF GLIOMAS AND FUNCTIONAL OUTCOME OF THEIR PATIENTS
Katsushi Taomoto (Japan)

08:24 P015
		

Ian F. Parney (USA)08:27 P016
		

Kaori Sakurada (Japan)

AWAKE CRANIOTOMY AND ELECTROPHYSIOLOGICAL MAPPING IN A HIGH FIELD INTRA-OPERATIVE MRINEW INTRAOPERATIVE MRI SYSTEM IN BRAIN TUMOR SURGERY- 20 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

08:30 P017
		
08:33 P018

NOVEL SURGICAL TECHNIQUE OF RADICAL REMOVAL FOR GLIOMAS

Kyung Gi Cho (Korea)

		

DISSECTION AND SEPARATION OF HIGH GRADE GLIAL TUMORS FROM BRAIN TISSUE BY USINGMETHALIC DISSECTOR WITH THE CAPABILITY OF PRODUCING VIBRATION
Cengiz Cokluk (Turkey)

08:36 P019
		

Cengiz Cokluk (Turkey)

08:39 P020
		

Chun Kee Chung (Korea)

THE OPERATION OF PIAL SYNANGIOSIS IN THE SURGICAL TREATMENT OF MALIGNANT GLIAL TUMORSTHE CLINICAL RESULTS OF FIVE CASES OF INSULAR TUMOR RESECTION

08:42 P021 KEYHOLE SURGERY IN THE TREATMENT OF GLIOMAS		Toshihiko Iuchi (Japan)
Keynote08:50 KN01 SURGERY ON PATIENTS WITH SYMPTOMATIC LOW GRADE GLIOMA IN CRITICAL BRAIN AREA
		
Christianto Lumenta (Germany)
09:20 O017
		
09:30 O018

AWAKE SURGERY DURING RESECTION OF INSULAR GLIOMAS

Ruben Dammers (Netherlands)		

AWAKE CRANIOTOMY FOR THE PRESERVATION OF THE BRAIN FUNCTIONS INCLUDING LANGUAGE,
MOTOR, AND HIGHER BRAIN FUNCTIONS
Kuniaki Saito (Japan)

09:40 O019
Cancelled

CRANIAL SURGERY AND NAVIGATION BY USING LOW-FIELD-STRENGTH INTRAOPERATIVE MAGNETICRESONANCE IMAGING: EXPERIENCE IN 251 PATIENTS

09:50 O020

DEVELOPMENT OF THE COMPACT MAGNETIC RESONANCE IMAGING SYSTEM FOR INTRAOPERATIVEIMAGING.
Akio Morita (Japan)

		

10:00 O021
		

PRESURGICAL PLANNING FOR CEREBRAL GLIOMA WITH PYRAMIDAL TRACT INVOLVEMENT IN A
STEREOSCOPIC DTI-BASED VIRTUAL REALITY ENVIRONMENT
Qiu Tianming (China)

10:10 O022
		

Giorgio Carrabba (Italia)

10:20 O023
		

ROLE OF DTI FIBER TRACKING IN PREDICTING THE EXTENT OF RESECTION IN GLIOMA SURGERYOPTICAL COHERENCE TOMOGRAPHY FOR INTRAOPERATIVE ANALYSIS OF GLIOMA TISSUE MICROSTRUCTURE
AND LIGHT ATTENUATION AS A NOVEL TECHNIQUE TO CONTROL THE EXTENT OF RESECTION
Alf Giese (Germany)lSpecial Seminar: 5-ALA
Sponsored by SBI ALA PROMO Co., Ltd.

Chairperson: Soichiro Shibui (Japan)

10:45 IL02
		
11:45 P022
		

GLIOLAN IN THE THERAPY OF MALIGNANT GLIOMAS: QUO VADIS?

Walter Stummer (Germany)				

SIGNIFICANCE OF PORPHYRINS IN BLOOD AND URINE OF BRAIN TUMOR PATIENTS THAT UNDERWENT
5-ALA ADMINISTRATION
Satoshi Utsuki (Japan)

lLunchtime Symposium: Targeting Integrins in Glioblastoma Treament
Sponsored by Merck Serono

Chairpersons: Roger Stupp (Switzerland)		
Yong-Kwang Tu (Taiwan)

12:00 LSy01 WELCOME AND INTRODUCTION
		Yong-Kwang Tu (Taiwan)
12:10 LSy02 GLIOBLASTOMA AND CURRENT TREATMENT MODALITIES		Michael Weller (Switzerland)
12:25 LSy03 INTEGRINS: NOVEL TARGETS IN GLIOBLASTOMA TREATMENT
		Joerg-Christian Tonn (Germany)
12:45 LSy04 PRE-CLINICAL PROOF OF PRINCIPLE FOR INTEGRIN INHIBITORS IN GLIOBLASTOMA TREATMENT		Tom Mikkelsen (USA)
13:05 LSy05 TARGETED GLIOBLASTOMA THERAPIES: INTERACTIVE CASE STUDIES		David A. Reardon (USA)- 21 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

13:30 LSy06 ONGOING CLINICAL TRIALS		Roger Stupp (Switzerland)
13:45 LSy07 DISCUSSION AND CLOSING REMARKS		Roger Stupp (Switzerland)lInvited Lecture
Chairperson: Hideho Okada (USA)14:10 IL03
		

ENGINEERING T CELLS FOR ADOPTIVE THERAPYCarl June (USA)lImmunology
Chairpersons: Jun-ichi Kuratsu (Japan)		
Ryuya Yamanaka (Japan)

		

SYSTEMIC INHIBITION OF TRANSFORMING GROWTH FACTOR β IN GLIOMA-BEARING MICE IMPROVED THE
THERAPEUTIC EFFICACY OF PEPTIDE VACCINATIONS TARGETING GLIOMA-ASSOCIATED ANTIGENS
Ryo Ueda (USA)

15:20 O025

INTERFERON-αSIGNALING IN THE BRAIN PLAYS A MAJOR ROLE IN IMMUNE SURVEILLANCE DURING		

Mitsugu Fujita (USA)

15:30 O026

AUTOLOGOUS DENDRITIC CELLS-BASED IMMUNOTHERAPY FOR MALIGNANT GLIOMAS- A PHASE IIPROSPECTIVE RANDOMIZED CLINICAL TRIAL
Der-Yang Cho (Taiwan)

15:10 O024

		

15:40 O027
		

15:50 O028
		

16:00 O029
		

16:20 P023

GLIOMA-GENESIS IN MICE

PHASE II CLINICAL TRIAL OF WT1 VACCINATION AGAINST RECURRENT GLIOBLASTOMA WITHANALYSES OF WT1 SPECIFIC CYTOTOXIC T LYMPHOCYTESNaoya Hashimoto (Japan)
PHASE I/IIA TRIAL OF AUTOLOGOUS FORMALIN FIXED TUMOR VACCINE IN TREATMENT OF NEWLYDIAGNOSED GLIOBLASTOMA MULTIFORME.
Yoshihiro Muragaki (Japan)
TYPE-1 DENDRITIC CELL VACCINES IN COMBINATION WITH POLY-ICLC - ASSOCIATION BETWEENPOSITIVE TETRAMER RESPONSE AND 6-MONTH PROGRESSION-FREE SURVIVAL
Hideho Okada (USA)		ELECTROLOADED DENDRITIC CELLS WITH WHOLE TUMOR LYSATE ELICIT ENHANCED INDUCTION OF
TUMOR-SPECIFIC IFNγ PRODUCING CELLS IN PATIENTS WITH GLIOBLASTOMA
Shusuke Moriuchi (Japan)

16:23 P024
		

Hidemitsu Sato (Japan)

16:26 P025
		

CYTOTOXIC T LYMPHOCYTES INDUCTION WITH HLA-A2402-RESTRICTED GLIOMA SPECIFIC PEPTIDES

Characterization of a novel tumor-associated antigen for targeted toxin therapy ingliomas.
Oscar Persson (Sweden)

lGene Therapy
Chairpersons: Takashi Tamiya (Japan)
		Tomoki Todo (Japan)

Keynote16:30 KN02 The Role of MicroRNAs in Malignant Glioma		Antonio Chiocca (USA)
17:00 O176
		

17:20 O030

TREATMENT OF OPERABLE HIGH-GRADE GLIOMA WITH SITIMAGENE CERADENOVEC GENE THEREAPYAND GANCICLOVIR: RESULTS OF A RANDOMIZED PHASE III TRIAL
Zvi Ram (Israel)		

INDUCIBLE ONCOLYTIC TRANSFORMATION OF REPLICATION-DEFICIENT VIRUS FOR THE CELL-BASEDVIROTHERAPY
Hiroshi Nakashima (USA)

17:30 O031
		

Kazuhiko Kurozumi (USA)

17:40 P026
		

ONCOLYTIC VIRUS THERAPY OF GLIOMA SENSITIZES GLIOMA CELLS TO CILENGITIDE TREATMENT.

Tumoricidal bystander effect-mediated suicide gene therapy of glioma using
genetically engineered bone marrow-derived mesenchymal stem cells
Shinji Amano (Japan)- 22 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

17:43 P027
		

An efficient targeted gene therapy using brain tumor-specific promoter

Toshio Yawata (Japan)

May 12 (Tue)Room 3lPediatric Neuro-Oncology I
Chairperson: Takaaki Yanagisawa (Japan)

08:00 P028
		

08:03 P029

LONG-TERM OUTCOME OF 23 CONSECUTIVE CHILDREN WITH PRIMARY INTRADURAL SPINALTUMORS TREATED AT THE MEDICAL UNIVERSITY OF VIENNA (1997-2008)
Thomas Czech (Austria)		Effectiveness of multi-staged operations with combined chemotherapies for hugemalignant infantile brain tumors in the first year of life
Naoki Kagawa (Japan)

08:06 P030
		

Su G Berrak (Turkey)

08:09 P031

WHICH THERAPY WORKS BETTER IN METASTATIC CHOROID PLEXUS CARCINOMAS?

		

99 Tc Sestamibi scan differentiates tumor from other contrast enhancing tissue inchoroid plexus tumors - Case report and Review of Literature
Vivek Subbiah (USA)08:12 P032
		Yuji Uematsu (Japan)

08:15 P033
		

08:18 P034

Adjuvant chemoradiation for mixed germ cell tumors

OVER A 10-YEAR SURVIVAL AND COMPLETE RESPONSE OF A PATIENT WITH DIFFUSE INTRINSICBRAINSTEM GLIOMA (DBSG) TREATED WITH ANTINEOPLASTONS (ANP)
Robert A. Weaver (USA)		

Improved response of pontine glioma with simultaneous radiochemotherapy: resultsof a retrospective image analysis
Liunan Li (USA)08:21 P035
		

Qianxue Chen (China)

08:24 P036

Tactics For Diagnosis and Surgical Treatment of Brain Stem Tumors		Profile of Patients with Medulloblastoma at the Philippine General Hospital: a Six-Year
Review
Jessie T. Colacion (Philippines)

08:27 P037
		

Naoyuki Ohe (Japan)

08:30 P038
		

08:33 P039
		

08:36 P040
		

Results of treatment for medulloblastoma in our instituteCan absolute lymphocyte count really be a prognostic indicator for overall survival
in patients with Medulolblastoma?
Digvijaya D. Navalkele (USA)Integrating Complexity, Therapeutic Recreation, and Radiotherapy in Multidisciplinary
Medical Team on Reducing Anesthesia/Sedation Requirement for Toddlers and YoungChildren with Brain Tumor
I-Tsun Chiang (Taiwan)
Implications of Complexity: Leisure Participation on Primary Caregivers and HospitalizedChildren with Brain Tumor
I-Tsun Chiang (Taiwan)––––––––––––––––––––––––– Break –––––––––––––––––––––––––

Chairpersons: Byung-Kyu Cho (Korea)
		Thomas Czech (Austria)
		
Tai-Tong Wong (Taiwan)

08:50 O032
		
09:00 O033
		

09:10 O034
		

MEDULLOBLASTOMA : THE ROLE OF TOTAL TUMOR REMOVAL TO AVOID RECURRENCE

Eka Wahjoepramono (Indonesia)

OPTIMIZING THE PHYSICAL AND BIOLOGICAL PARAMETERS OF RADIOTHERAPY IN AVERAGE-RISK
MEDULLOBLASTOMA
Tejpal Gupta (India)
DO MEDULLOBLASTOMAS IN ADOLESCENTS HAVE A DISTINCT MOLECULAR SIGNATURE & DIFFERENTTUMOR BIOLOGY?
Wan-Yee Teo (USA)- 23 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

09:20 O035
		

09:30 O036
		

09:40 O037

Autologous hematopoetic stem cell transplantation for children with high risk brain
tumorsHo Joon Im (Korea)
Clinicopathological features of Atypical Teratoid/Rhabdoid Tumors: its diagnosis andtumor growth factor
Hidehiro Oka (Japan)

		PRE-CLINICAL TESTING OF COMBINATION RADIATION PLUS HISTONE DEACETYLASE INHIBITOR
THERAPY IN TREATING ATYPICAL TERATOID RHABDOID TUMOR
Rintaro Hashizume (USA)09:50 O038
		

Johannes E.A. Wolff (USA)

10:00 O039
		

Johannes E.A. Wolff (USA)10:10 O040
		

Michael Karremann (Germany)

10:20 O041

Atypical Choroid Plexus Papilloma: 2008 Interim Analysis of the CPT-SIOP-2000 Study
Metastatic Choroid Plexus Tumors - Data of the CPT-SIOP-2000 Study
Pediatric Gliosarcomas: Clinical and Epidemiological Characteristics

		Role of Temozolomide for The Treatment of Newly Diagnosed Diffuse Brainstem Glioma
in Children- Experience in A Single Institution
Kuo-Liang Chiang (Taiwan)

10:30 O042
		

Yutaka Sawamura (Japan)

10:40 O043
		

Guihuai Wang (China)

10:50 O044		

11:00 O045

Role of surgery for optic pathway/hypothalamic astrocytomas in children
Prognositic analysis of 220 patients with intramedullary spinal cord ependymomas

Grading system for diagnosis and treatment of intracranial nongerminomatous
malignant germ cell tumors
Xiang Huang (China)		

OPTIMAL TREATMENT STRATEGY FOR INTRACRANIAL GERM CELL TUMORS: SINGLE INSTITUTIONANALYSIS.
Masayuki Kanamori (Japan)

11:10 O046
		

Yi-Wei Chen (Taiwan)

11:20 O047
		

The Optimal Radiation Volume and Dose for Intracranial Germinoma

Germ Cell Tumors in the Basal Ganglia: Clinical Outcomes and Diagnostic Utility of
Positron Emission Tomography (PET)
Byung-Kyu Cho (Korea)lLunchtime Symposium
Sponsored by American Family Life Assurance Company of Columbus andSpecified Nonprofit Corporation Gold Ribbon Network
Chairpersons: Jong-Hyun Kim (Korea)
		Michael Vogelbaum (USA)

12:00 Lsy08 Cost Effectiveness of Brain Tumor Therapy
Clifford Schold (USA)		
12:20 Lsy09 Health care and socio-medical support services directed to pediatric brain tumours
patients and their families in Canada.
Eric Bouffet (Canada)		
12:40 Lsy10 Psychosocial support for children and adolescents with brain tumors in
Irene Slavc (Austria)
		lLectures Open to the Public
Sponsored by American Family Life Assurance Company of Columbus andSpecified Nonprofit Corporation Gold Ribbon Network
Chairperson: Yukitaka Ushio (Japan)

14:00 O048
		

Stephen Sands (USA))

14:30 O049
		Elana Farace (USA)

Late Effects of Treatment for Pediatric Brain Tumor Patients
Caring for the Caregiver of a Brain Tumor Patient- 24 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

15:00 O050
		

Late Endocrine Effects in Childhood Brain Tumors

Susumu Yokoya (Japan)––––––––––––––––––––––––– Break –––––––––––––––––––––––––
Chairperson: Masao Matsutani (Japan)

15:40 O051
		

Yutaka Sawamura (Japan)

16:25 O052
		Mark Kieran (USA)

16:35 O053
		

Jun A. Takahashi (Japan)

17:20 O054
		W.K. Alfred Yung (USA)

Pediatric Brain Tumor: Current status of Patient's Care and A Problems in Japan
Commentary

Adult Brain Tumors
Commentary––––––––––––––––––––––––– Break –––––––––––––––––––––––––
Chairpersons: Akiko Higuchi (Japan)
		Mike Traynor (USA)
17:40 O055
		

17:50 O056

Pediatric Brain Tumors - From Research to Hope

Mike Traynor (USA)		The European brain tumour patient and caregiver community - achievements,
challenges and the pursuit of hopeDenis Strangman (Australia)

18:00 O057
		

Akiko Higuchi (Japan)

The Reality of Brain Tumours: Current status and future perspective in Asian Countries

May 12 (Tue)LoungelHands-On Seminar: Skull Base Technique
Chairperson: Kazuhiko Mishima (Japan)

11:00 LSe03 Anterior Petrosal Approach		Nobutaka Kawahara (Japan)
11:25 LSe04 Posterior Petrosal Approach		Mitsuhiro Hasegawa (Japan)

May 13 (Wed)Room 1lHoshino Award Selection
Chairperson: Motoo Nagane (Japan)
Panel of Judges:		
Mitchel Burger (USA) , Susan Chang (USA), Victor Levin (USA)		Erwin van Meir (USA), Michael Vogelbaum (USA)
		
		
		

Martin van den Bent (Netherlands), Rolf Bjerkvig (Norway)
Irene Slavc (Austria), Michael Weller (Switzerland)
Wolfgang Wick (Germany)				Kaya Aksoy (Turkey), Kyung Gi Cho (Korea), Yuanli Zhao (China)
Masao Matsutani (Japan), Hideyuki Saya (Japan)

08:00 P041
		Yaodong Zhao (China)

08:03 P042
		Shou Xuefei (China)

08:06 P043
		

Endothelial Cell Transdifferentiation of Human Glioma Stem/ Progenitor Cells In vitro
The New Diagnosis and Treament of Pituitary Apoplexy

THE MIR-17/92 POLYCISTRON IS AMPLIFIED AND UP-REGULATED IN SONIC HEDGEHOG-DRIVENMEDULLOBLASTOMAS AND INDUCED BY N-MYC IN SONIC HEDGEHOG-TREATED CEREBELLARNEURAL PRECURSORSPaul A. Northcott (Canada)- 25 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

08:09 P044
		

08:12 P045

MULTIPLE RECURRENT GENETIC EVENTS CONVERGE ON CONTROL OF HISTONE LYSINE METHYLATIONIN MEDULLOBLASTOMAPaul A. Northcott (Canada)		

MEDIP-CHIP AND MEDIP-SEQ IDENTIFY NOVEL EPENDYMOMA TUMOUR SUPPRESSOR GENES
THROUGH DELINEATION OF THE EPENDYMOMA EPIMETHYLGENOME
Stephen Mack (Canada)

08:15 P046
		

Xuhui Bao (China)

08:18 P047
		Marie de Tayrac (France)

08:21 P048
		

Moran Artzi (Israel)

08:24 P049

Clinical Diagnosis of Optic Nerve Hemangioblastoma
Gene expression meta-analysis identifies grading and survival markers in anaplastic glioma
Multiparameteric MR approach for tissue characterization of patients with GBM

		NG2 Expression Establishes a Link Between Neural Precursors and Cancer Stem Cells
in Glioblastoma
Talal M. Fael Al-Mayhami (UK)08:27 P050
		

Aliasgar Moiyadi (India)

08:30 P051
		

Alasdair G. Rooney (UK)08:33 P052
		

Sith Sathornsumetee (USA)08:36 P053
		

08:39 P054
		

08:42 P055

UNUSUAL CASE OF RADIATION-INDUCED GROWING TERATOMA SYNDROME
Causes and correlates of distress and major depression in high-grade glioma
BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL

PATIENT FUNCTIONAL STATUS IS STRONGEST CORRELATE OF CHALLENGING BEHAVIOUR AFTERBRAIN TUMOUR
Eng-Siew Koh (Australia)
Detailed prospective neuropsychological, activity of daily living and endocrine
function assessment in children with craniopharyngioma treated with stereotactic
conformal radiotherapy
Debnarayan Dutta (India)		

Human neural stem cells can target and deliver therapeutic genes to breast cancer
brain metastases
Kyeung Min Joo (Korea)

08:45 P056
		

Athina Marantidou (France)

08:48 P057
		

Fonnet E Bleeker (Netherlands)

08:51 P058
		

08:54 P059

Steroid Requirements during Radiotherapy for Malignant Gliomas
Mutational profiling of high grade gliomas reveals inactivating mutations in IDH1

Genomic Profiling of Intracranial Germ Cell Tumors with Single Nucleotide
Polymorphism Array
Keita Terashima (USA)		

PRESENCE OF AN ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM AS A FAVORABLE
PROGNOSTIC MARKER IN PATIENTS WITH GLIOBLASTOMA
Kerrie L McDonald (Australia)

08:57 P060
		

Jiun-lin Yan (Taiwan)

09:00 P061
		

09:03 P062
		

09:06 P063
		

09:09 P064
		

LONG TERM FOLLOW UP OF PATIENT WITH ACROMEGALY AFTER LINAC RADIOSURGERY

DO MEDULLOBLASTOMAS IN ADOLESCENTS HAVE A DISTINCT MOLECULAR SIGNATURE & DIFFERENTTUMOR BIOLOGY?
Wan-Yee Teo (USA)
Aberrant expression of GDF-15 contributes to proliferation and immune escape ofmalignant gliomas
Patrick Roth (Swiss)
Personalized chemotherapy based on O6-methylguanine-DNAmethyltransferase(MGMT) expression pattern for glioma patients: experience of 57 cases
Junping Zhang (China)
CDK4/6 SMALL MOLECULE INHIBITOR PD-0332991 DEMONSTRATES ANTI-TUMOR ACTIVITY AGAINSTAN INTRACRANIAL GLIOBLASTOMA XENOGRAFT LACKING p16 FUCNTION
Karine Michaud (USA)- 26 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

09:12 P065
		

PATIENT-SPECIFIC VIRTUAL CONTROLS CAN BE USED TO SIMULATE AND PREDICT RESPONSE TORADIATION THERAPY IN INDIVIDUAL GLIOBLASTOMA PATIENTS
Kristin R. Swanson (USA)

09:15 P066
		

Jun Fu (China)

09:18 P067
		

Autophagy Induced by Valproic Acid is Associated with Oxidative Stress in Glioma Cell Lines

Management of pituitary adenoma with stereotactic radiotherapy at Princess
Margaret Hospital.
Nikhilesh Patil (Canada)lBasic Science I, Genome - Proteome
Chairpersons: Zhong-ping Chen (China)		Koichi Ichimura (UK)		
Do-Hyun Nam (Korea)

09:25 P068
		

09:28 P069
		

09:31 P070
		

09:34 P071
		

09:37 P072
		

09:40 P073
		

09:43 P074
		

09:46 P075

Genomewide Analysis of Loss of Heterozygosity in Glioblastoma using the SNP mapping
array and the PCR with multiple microsatellite markers
Masahiro Mizoguchi (Japan)
Molecular allelokaryotyping of malignant glioma by high-resolution single
nucleotide polymorphism (SNP) oligonucleotide genomic microarray
Hideo Nakamura (Japan)
An ANOCEF genomic and transcriptomic microarray study of the response toradiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.
Francois Ducray (France)
Selective Expression of a Subset of Neuronal Genes in Oligodendrogliomawith
Chromosome 1p Loss
Akitake Mukasa (Japan)
LOSS OF HETEROZIGOSITY AT 1p-19q INDUCES A GLOBAL CHANGE IN OLIGODENDROGLIAL TUMORGENE EXPRESSION.
Horacio Martinetto (Argentine)
Functional analysis of the proteome related to the chemotherapy sensitivity inanaplastic oligodendroglioma and anaplastic oligoastorocytoma
Nobuyuki Tsubota (Japan)
Establish the overall proteins reference database of human normal pituitary using
2D-HPLC combined with LTQ-Orbitrap MS
Rong Xie (China)

		CD52 protein may be a potential tumor marker of hemangioblastoma in central
nerval systerm with cDNA microarray filtration of the gene expression profiles
Xing-hua Ding (China)

09:49 P076
		Norihiko Saito (Japan)

09:55 O058
		

Koichi Ichimura (UK)

10:15 O059
		Jean Mosser (France)

10:25 O060
		

Jeffrey S. Chang (USA)10:35 O061

Genome-wide analysis of gene expression during brain metastasis formation
MOLECULAR GENETIC SIGNATURES THAT DEFINES SUBTYPES OF HUMAN GLIOMAS
Integration of genomic alterations and expression profiling in Glioblastoma Multiforme
GENOME-WIDE ASSOCIATION STUDY OF ADULT GLIOBLASTOMA RISK		GENETIC DIVERSITY ASSOCIATED WITH SURVIVAL IN MALIGNANT GLIOMAS IDENTIFIED BY LINKAGE
DISEQUILIBRIUM-BASED ANALYSIS OF HAPLOTYPE BLOCK REGIONS OF DNA REPAIR GENES
Francis Ali-Osman (USA)10:45 O062
		

Dietmar Krex (Germany)

DIFFERENTIAL GENE-EXPRESSION IN RECURRENT GLIOBLASTOMA MULTIFORME

lLecture from SNO
Chairperson: Susan Chang (USA)

11:00 KN03
		

COMPREHENSIVE GENOMIC CHARACTERIZATION OF GLIOBLASTOMA: THE CANCER GENOME ATLASEFFORT.
Webster Cavenee (USA)- 27 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

lLunchtime Seminar: New Horizons: Implants Medication for Malignant Glioma Operation
Sponsored by Eisai Co., Ltd.

Chairperson: Kazuhiko Sugiyama (Japan)

12:00 LSe05 Experiences with locoregional chemotherapy for glioblastoma during resection
Manfred Westphal (Germany)		lLecture from EANO
Chairperson: Michael Weller (Switzerland)

13:00 KN04
		

The future treatment of anaplastic glioma: lessons from NOA-04 and beyond

Wolfgang Wick (Germany)lOngoing Clinical Trials and the Future Direction of Glioma Treatment
Chairpersons: Ryo Nishikawa (Japan)		Martin van den Bent (Netherlands)
		
W.K. Alfred Yung (USA)

14:00 O063
		Multi-arm Combinatorial Study of Signal Transduction Modulators Using a Sequential
Accrual Design – A Report of NABTC 0502
Mark Gilbert (USA)14:25 O064
		

Progression-free survival: an important endpoint in neuro-oncology clinical trials
Michael Prados (USA)

14:50 O065
		

MULTICENTER PHASE II TRIAL OF TALAMPANEL WITH STANDARD RADIATION AND TEMOZOLOMIDE IN
PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: REPORT OF TWO YEAR SURVIVAL DATA
Stuart A. Grossman (USA)

15:15 O066
		

Wolfgang Wick (Germany)

15:40 O067
		

16:05 O068
		

ONGOING CLINICAL TRIALS AND THE FUTURE DIRECTION OF GLIOMA TREATMENT

The result of a clinical trial for malignant gliomas by JCOG-Brain Tumor Study Group(JCOG 0305)
Soichiro Shibui (Japan)
Current clinical trials of glioma therapy and situations of neurooncology practicein Korea
Yong-Kil Hong (Korea)

lSpecial Lecture
Sponsored by Chugai Pharmaceutical Co.,Ltd.

Chairperson: Webster Cavenee (USA)

16:40 IL04
		

Brain Tumor Stem Cells: New Insights and Challenges in Human and Mouse Models
Peter Dirks (Canada)lStem Cell Science Posters
Chairperson: Masamichi Takahashi (Japan)

17:50 P077
		

17:53 P078
		

17:56 P079
		

HYPOXIA PROMOTES EXPANSION OF THE CD133-POSITIVE GLIOMA STEM CELLS THROUGH
ACTIVATION OF HIF-1α
Akio Soeda (USA)
Effects of hypoxia on expression of a panel of stem cell and chemosensitivity
markers in glioblastoma cell line-derived spheroids
Jesper Kolenda (Denmark)Cell motility features are identified in the CD133-positive glioma and endothelial
progenitor cells
Ping-Pin Zheng (Netherlands)

17:59 P080
Cancelled
18:02 P081
		

Takuichiro Hide (Japan)

18:05 P082
		

Jasti S. Rao (USA)18:08 P083
		

GLIOBLASTOMA TUMOUR INITIATING CELLS DEMONSTRATE VEGF BUT NOT PDGF AUTOCRINE SIGNALLING
Establishment of artificial Glioblastoma initiating cells in mouse
CD133 ON STEM CELLS IS REQUIRED FOR APOPTOTIC INDUCTION IN GLIOMAS

Tumor stem-like associated antigens and their irradiations improve the effect ofdendritic cell-based vaccination against human glioma
Wei Hua (China)- 28 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

18:11 P084
		

18:14 P085
		

18:17 P086
		

18:20 P087
		

18:23 P088
		

Immunosuppressive B7-H1 Protein is Expressed by Differentiated Glioma Cells but not
Glioma Stem Cells
Ian F. Parney (USA)
B7-H1 is correlated with the malignancy grade of human astrocytic tumors but it is
not the privilege of brain tumor stem-like cells
Yu Yao (China)
EXPRESSION LEVEL OF STEM CELL MARKERS IS ASSOCIATED WITH THE SOURCE OF NEUROSPHEREMEDIA USED FOR GLIOBLASTOMA STEM CELL CULTURE.
Tony Avril (France)
AN EVALUATION OF THE NEURAL STEM CELL MARKER NG2 AS A BIOMARKER OF DISEASE IN PATIENTSWITH GLIOBLASTOMAColin Watts (UK)
Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood-Derived Mesenchymal
Stem Cells against Intracranial Glioma
Sin-Soo Jeun (Korea)lHoshino Award Ceremony
18:30

May 13 (Wed)Room 2lDiagnostic Radiology
Chairperson: Hiroyuki Momota (Japan)

08:00 P089
		Yasushi Shibata (Japan)

08:03 P090
		

Yasushi Shibata (Japan)

08:06 P091

Brain Easy Analysis Tool For 201Tl SPECT in Brain Tumors
123I-IMP SPECT in Brain Tumor: Anatomical Standardized Statistical Mapping		The application of Susceptibility Weighted magnetic resonance Imaging (SWI) to
diagnosis and treatment of meningiomas.
Kanji Mori (Japan)

08:09 P092
		

Mikhail Chernov (Japan)

08:12 P093
		

08:15 P094
		

08:18 P095
		

08:21 P096
		

08:24 P097
		

08:27 P098
		

08:30 P099
		

08:33 P100
		Choline-enhanced proton MRS of brain tumors

PREOPERATIVE EVALUATION BY PROTON MAGNETIC RESONANCE SPECTROSCOPY IN THE GRADING OF
GLIOMAS
Shinya Oshiro (Japan)
Modified 11C-Methionine PET imaging to distinguish radiation necrosis from recurrent
gliomaShunsuke Takenaka (Japan)
Matching analysis of PET and chemical shift imaging on proton MRS in patients withsupratentorial glioma
Hirohito Yano (Japan)
Augmenting Intraoperative MRI with Preoperative DTI and fMRI by Simulation of Brain
Deformation Using Mathematical Model Based on Thin-Plate Splines:A Preliminary Research
Cheng-Jun Yao (China)
The Value of rCBV Ratio in Perfusion MR for Differentiating Radiation Necrosis from
Tumor Recurrence in High Grade Glioma; comparison with 18F-FDG and 11C-Methionine PETYong Hwy Kim (Korea)
Evaluation of glioma grading on MR imaging: Diagnostic value of minimum apparent
diffusion coefficient compared with positron-emission tomography
Yoshitaka Asano (Japan)
Glioblastoma treated with postoperative radio-chemotherapy: Prognostic value ofapparent diffusion coefficient at MR imaging
Fumiyuki Yamasaki (Japan)
DIFFUSION-WEIGHTED IMAGING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED WITH
BEVACIZUMAB
Kevin P. Becker (USA)- 29 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

08:36 P101
		

Evaluation of anti-angiogenic therapy response in patients with GBM; a Homodynamic
Response Imaging study
Dafna Ben Bashat (Israel)

08:39 P102

PROGNOSTIC SIGNIFICANCE OF GROWTH KINETICS IN NEWLY DIAGNOSED GLIOBLASTOMA: A ROLE
FOR PATIENT-SPECIFIC VIRTUAL CONTROLS		Kristin R. Swanson (USA)
Chairpersons: Takanori Ohnishi (Japan)		Robert Grant (Scotland)
Keynote08:50 KN05 MR Metabolic and Physiological Imaging of Patients with Glioma
Sarah Nelson (USA)		
09:20 O069
		

09:30 O070
		

Histogram analysis of perfusion MR imaging data for the assessment of tumor
response during glioma therapy
Se-Hyuk Kim (Korea)
Dynamic perfusion MR images can predict the pseudoprogression mimicking true
progression in the treatment of newly diagnosed glioblastoma
Doo-Sik Kong (Korea)

lNovel Treatment Approach
Chairpersons: Takamitsu Fujimaki (Japan)
		
Xuejun Yang (China)

10:30 P103
		

10:33 P104
		

10:36 P105
		

10:40 O071
		

10:50 O072
		

11:00 O073
		

11:10 O074		

11:20 O075
		

Effectiveness of Gorei-San ( Wuling San ) for eliminating brain edema due to malignant
brain tumors
Akimune Hayashi (Japan)
Image guided Convection-enhanced delivery of nimustine hydrochloride (ACNU) inrecurrent glioma patients
Ryuta Saito (Japan)
CONVECTION ENHANCED DELIVERY OF NIMUSTINE HYDROCHLORIDE (ACNU) WITH SYSTEMICADMINISTRATION OF TEMOZOLOMIDE IN RECURRENT GLIOMA PATIENTS
Yukihiko Sonoda (Japan)
The anti-tumor effect of convection-enhanced delivery of micelle-Am80 with systemic
administration of Temozolomide.
Michiko Yokosawa (Japan)
An implantable magnetic breather pump for metronomic convection enhanced
delivery of biological agents in malignant gliomas
Thomas C. Chen (USA)Intracerebral administration of CpG oligonucleotide for patients with recurrent
glioblastoma.A phase II study.
Renata Ursu (France)
Biodistribution and imaging studies on transferrin targeting PEG liposome
encapsulating both BSH and iodine contrast agent by convection enhanced delivery
on rat glioma for experimental boron neutron capture therapy
Shiro Miyata (Japan)
Intraoperative photodynamic diagnosis and therapy for malignant glioma using
second-generation photosensitizer Talaporfin sodium
Jiro Akimoto (Japan)

lLunchtime Seminar
Sponsored by Daiichi-Sankyo Co., Ltd.

Chairperson: Ryo Nishikawa (Japan)

12:00 LSe06 Molecularly Targeted Therapies for Glioblastoma: New Approaches for Personalized
Medicine
Paul Mischel (USA)		- 30 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANlBasic Science II
Chairpersons: Shiyuan Cheng (USA)		
Beatrice Malmer (Sweden)		Motoo Nagane (Japan)

Keynote13:00 KN06 Brain tumor initiation and development, influence of cancer stem-like cells.
		Rolf Bjerkvig (Norway)
13:30 O076
		
13:50 O077
		

14:10 O078
		

14:20 O079
		

14:40 O080

Mutational profiling of high grade gliomas reveals inactivating mutations in IDH1

Fonnet E Bleeker (Netherlands)

KCN1, A novel SMALL MOLECULE HIF inhibitor PREVENTS GLIOMA growth through bindingof Plectin-1 and inhibition of the Hsp90 pathway
Erwin G Van Meir (USA)
Direct Tyrosine Phosphorylation of GSTP1 by EGFR induces JNK activation in
glioblastoma cells
Tatsunori Okamura (USA)
Quantitative expression analysis revealed significant correlation of EGFR variant III(vIII) and Notch expression in glioblastoma
Koji Yoshimoto (Japan)

		

EGFRvIII PREFERNTIALLY ACTIVATES STAT5 AND GAB1, CAN BE ACTIVATED BY FORCED DIMERIZATION
AND LOCATES TO THE NUCLEUS
Oliver Bogler (USA)

14:50 O081
		

Soma Ghasimi (Sweden)

Association of polymorphic variants in EGFR and LRIG2 and meningioma risk––––––––––––––––––––––––– Break –––––––––––––––––––––––––
Chairpersons: Rolf Bjerkvig (Norway)		
Oliver Bogler (USA)		Erwin G. Van Meir (USA)

15:30 O082
		

A novel p53 bystander effect: paracrine induction of apoptosis in tumor cells throughthe induction of Galectin-3 secretion
Erwin G. Van Meir (USA)

15:40 O083
		

Joachim Steinbach (Germany)

15:50 O084		

16:00 O085

P53: AN ANTAGONIST OF EGFR-MEDIATED METABOLIC ACTIVITY IN HUMAN MALIGNANT GLIOMA CELLSSPONTANEOUS TRANSFORMATION OF p53 NULL SUBVENTRICULAR ZONE CELLS IN VIVO, AND USE IN
ORTHOTOPIC THERAPEUTIC TESTING
Rintaro Hashizume (USA)		

ADP-ribosylation Factor 6 Regulates Glioma Cell Invasion through the IQ-domainGTPaseactivating protein 1-Rac1-mediated Pathway
Shi-Yuan Cheng (USA)

16:20 O086
		

Mitsutoshi Nakada (Japan)

16:30 O087

ROLES OF SPHINGOSINE-1-PHOSPHATE RECEPTOR IN GLIOMA CELL PROLIFERATION AND PATIENTS SURVIVAL		

EPHA3 REGULATES CANCER PROGENITOR CELL SELF-RENEWAL AND PROLIFERATION IN GLIOMA
NEUROSPHERE CULTURES
Bryan W. Day (Australia)

16:40 O088
Cancelled

THE ALTERNATIVE TRKAIII SPLICE VARIANT, EXPRESSED BY NEUROBLASTOMAS AND GLIOBLASTOMAS,TARGETS THE CENTROSOME AND PROMOTES GENETIC INSTABILITY

16:50 O089
		

PRESENCE OF AN ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM AS A FAVORABLE
PROGNOSTIC MARKER IN PATIENTS WITH GLIOBLASTOMA
Kerrie L. McDonald (Australia)

17:10 O090		

Yanlei Guan (Japan)

17:20 O091
		

17:30 O092
		

PROGNOSTIC SIGNIFICANCE OF MICRORNA-196 IN GLIOBLASTOMA

Development of a novel mouse model of glioblastoma multiforme using lentiviral
vectors
Tomotoshi Marumoto (Japan)
PHENOTYPIC MODULATION OF EXPERIMENTAL GLIOMAS: PROGRESSION FROM GLIOMATOSISCEREBRI-LIKE LESIONS TO GLIOBLASTOMAJian Wang (Norway)- 31 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

17:40 O093
		

17:50 O094

ISOLATION AND CHARACTERIZATION OF INTERLEUKIN 13 RECEPTOR ALPHA2-SPECIFICHEPTAPEPTIDES
Waldemar Debinski (USA)		

Autologous SH3-domain GRB2-like 1 (SH3GL1) antibody as a novel serum marker specificto low-grade glioma
Tomoo Matsutani (Japan)

18:00 O095
		

Rainer Vormittag (Austria)

HIGH SOLUBLE P-SELECTIN AND LOW PLATELET COUNT AS THROMBOSIS RISK MARKERS IN GLIOMA PATIENTSMay 13 (Wed)Room 3lGlioma
Chairpersons: Yong-Kil Hong (Korea)		
Jun A. Takahashi (Japan)

08:00 P106
		
08:03 P107
		

08:06 P108

SURVIVAL OF PATIENTS WITH GLIOBLASTOMA MULTIFORME AT HARTFORD HOSPITAL

Alexandra Flowers (USA)SINGLE CENTER SURVIVAL OUTCOMES OF 167 GLIOBLASTOMA PATIENTS: BEFORE AND AFTERTEMOZOLOMIDEUfuk Abacioglu (Turkey)		Clinical outcomes of adult supratentorial grade 3 malignant gliomas in a single
institution
Yoshitaka Narita (Japan)

08:09 P109
		

Aya Shinomiya (Japan)

08:12 P110
		Glen H.J. Stevens (USA)08:15 P111
		

08:18 P112

Glucocorticoid-induced bone fracture in progressive glioma patients
NEWLY DIAGNOSED PREGNACY AND GLIOBLASTOMA MULTIFORME (GBM): AN ETHICAL COLLISION COURSE

Vntricular and Leptomeningeal Seeding in a Patient with Medullary Anaplastic
Oligodendroglioma
Young-Cho Koh (Korea)

		Long-term outcome of low-grade gliomas treated with radiotherapy-deferring
therapeutic policy
Yasuo Iwadate (Japan)

08:21 P113
		

Kazuya Aoki (Japan)

08:25 O096
		

Jeong Hoon Kim (Korea)

08:35 O097
		

Eudocia C. Quant (USA)08:45 O098
		

Considerations for diagnosis and treatment of classical gliomatosis cerebri
Clinical Outcome and Prognostic Factors of Gliomatosis Cerebri
CASE-CONTROL STUDY OF LONG TERM SURVIVORS OF PRIMARY GLIOBLASTOMAEFFECTS OF PREGNANCY ON NATURAL HISTORY OF WHO GRADE II GLIOMAS. A QUANTITATIVEANALYSIS OF THE TUMOR GROWTH RATES.
Luc Taillandier (France)lMetastatic Brain Tumors
Chairpersons: Akio Asai (Japan)
		Yong Gu Chung (Korea)

09:10 P114
		

Growth rates of metastatic brain tumors in non-small cell lung cancer; estimationfrom micro-metastasis
Heon Yoo (Korea)

09:13 P115
		Tomohiko Ozaki (Japan)

09:16 P116
		

Lumir Hrabalek (Czech)

09:19 P117
		

Ondrej Kalita (Czech)

PROGNOSTIC FACTORS IN 57 PATIENTS WITH METASTASTIC BRAIN TUMORS FROM BREAST CANCER.
Intramedullary spinal cord metastasis in breast carcinoma, case report.
Spinal cord metastasis of adenocarcinoma, case Report- 32 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

09:22 P118
		

09:25 P119
		

09:30 O099
		

09:50 O100

Complete response of a large recurrent metastatic brain tumor treated by CyberKnife:a case report and review of literature
Da-Tong Ju (Taiwan)
Continuous intrathecal treatment with methotrexate via "Ventricular port" forleptomeningeal dissemination of malignant tumors
Yusuke Tabei (Japan)
WHOLE-BRAIN RADIOTHERAPY VERSUS OBSERVATION AFTER RADIOSURGERY OR SURGERY OF 1-3
BRAIN METASTASES - RESULTS OF THE EORTC 22952-26001 PHASE III STUDY
Riccardo Soffietti (Italia)

		THE IMPACT OF CYST FORMATION AND TUMOR HEMORRHAGE ON LOCAL RECURRENCE IN BRAINMETASTASISHeon Yoo (Korea)

10:00 O101
		Peter Proemmel (Germany)

10:10 O102		NEOPLASTIC MENINGITIS - IS MRI AS SENSITIVE AS CSF CYTOLOGY?

Immunotherapy with CpG-ODN in neoplastic meningitis( for patients with neoplastic):
phase I trial.
Renata Ursu (France)lStrategies for Management of Patients With Brain Tumors in Emerging Countries
Chairperson: Jonathan Finlay (USA)Keynote11:00 KN07 Can we Develop Management Strategies for Adults and Children with Primary Brain
Tumors in Low Income Countries?
Jonathan Finlay (USA)		
11:30 O103		

Establishing myeloablative chemotherapy protocols in low-resource countries: thePakistan experience of the Cure2Children Foundation.
Lawrence B. Faulkner (Italy)

11:42 O104
		

Julette-Marie F. Batara (Philippines)

11:54 O105

Management of Brain Tumors in the Philippines		

THE CHALLENGES OF BUILDING AND SUSTAINING A PEDIATRIC NEURO-ONCOLOGY PROGRAM IN A
DEVELOPING COUNTRY
Ibrahim Qaddoumi (USA)12:06 O106
		

Emil Makimbetov (Kyrgyzstan)

12:18 O107
		

Stuart A. Grossman (USA)

12:20 O175
		CHILDHOOD BRAIN TUMORS INCIDENCE AND CARE IN THE KYRGYZ REPUBLICManagement of Cancer Pain in Developing Countries

THE ARGENTINE PEDIATRIC ONCOLOGY REGISTRY AS A TOOL TO EVALUATE THE SITUATION OF
CHILDREN WITH CNS TUMORS IN ARGENTINA.
Florencia Moreno (Argentine)

lEpidemiology
Chairperson: Soichiro Shibui (Japan)

13:00 P120
		

13:05 O108

Population Based Epidemioly of Central Nervous System (CNS) malignancies in theGirona province (Spain). Results of an 11 years survey (1994-2004).
Rafel Fuentes (Spain)		Descriptive Epidemiology of Cerebral Gliomas in Albania; Comparative Analysis during
the period of 1993-2004
Gentian Kaloshi (Republic of Albania)

13:15 O109
		

Daisuke Kita (Japan)

Age as predictive factor in glioblastomas: population-based study

lSellar/Parasellar Lesions
Chairpersons: Kaya Aksoy (Turkey)
		Fengping Huang (China)		Sun Ho Kim (Korea)

13:35 O110
		TUMOR TISSUE IDENTIFICATION IN THE PSEUDOCAPSULE OF PITUITARY ADENOMA: SHOULD THE
PSEUDOCAPSULE BE REMOVED FOR TOTAL RESECTION OF PITUITARY ADENOMA?
Sun Ho Kim (Korea)- 33 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

13:45 O111
		Management of pituitary adenoma with stereotactic radiotherapy at Princess
Margaret Hospital.
Nikhilesh Patil (Canada)

13:55 O112
		Jiun-lin Yan (Taiwan)

14:05 O113

Long Term Follow Up of Patient with Acromegaly after LINAC Radiosurgery		Several tips to avoid complications of intracystic chemotherapy with bleomycin for
craniopharyngioma in children
Akira Gomi (Japan)

14:15 O114
		

Ting-Rong Hsu (Taiwan)

14:25 O115
		

Seung-Ho Yang (Korea)

14:35 O116
		

Liang Chen (China)

Intracystic Bleomycin Therapy for Craniopharyngioma in Children.
Intratumoral bleomycin injection as a primary therapy for cystic craniopharyngioma
Differential Imaging Characters of the Tumors Involving the Cavernous Sinus

lMeningnioma, Chordoma
Chairpersons: Sang-Won Lee (Korea)
		Yang Weizhong (China)

14:50 O117
		

15:00 O118

RESULTS OF THE QUEEN SQUARE MENINGIOMA STUDY: EPIDEMIOLOGY, EPILEPTIC
CHARACTERIZATION, PRESENTING SYMPTOMS, TREATMENT, CLINICAL OUTCOME AND RECURRENCE.
Say Ayala (UK)		

Ki67 PROLIFERATION INDEX DOES NOT PREDICT SURVIVAL IN PATIENTS WITH NON-BENIGNMENINGIOMAS: ANALYSIS OF 86 CASES
Andrej Vranic (Slovenia)

15:10 O119
		

Ye Gong (China)

15:20 O120
		

15:30 O121
		

15:40 O122		ANALYSIS OF 56 MENINGIOMA CASES CLASSIFIED AS WHO GRADE III

CHORDOMA AND CHONDROSARCOMA OF THE SKULL BASE: COMPARATIVE ANALYSIS OF OUTCOMES
IN 30 PATIENTS
Jeong Hoon Kim (Korea)
TREATMENT WITH HIGH MARGINAL DOSE IS MANDATORY TO ACHIEVE LONG-TERM CONTROL OF
SKULL BASE CHORDOMAS AND CHONDROSARCOMAS BY MEANS OF STEREOTACTIC RADIOSURGERY
Tomoyuki Koga (Japan)
RESULTS OF PROTON BEAM THERAPY FOR CHORDOMA AND CHONDROSARCOMA OF THE SKULL
BASE: SHIZUOKA CANCER CENTRE EXPERIENCE
Yoko Nakasu (Japan)

lPoster Presentations: Neurosurgery
Chairperson: Junichi Adachi (Japan)

16:00 P121
		

THE FIRST FINGERPRINTS OF NEUROONCOLOGY IN PREHISTORIC ERA; PREHISTORIC TRAPENATED
SKULLS MAY BE THE FIRST ATTACT TO TREAT TUMORS IN NEUROONCOLOGY
Cengiz Cokluk (Turkey)

16:03 P122
		

Doo-Sik Kong (Korea)

16:06 P123
				

EXTENDED ENDOSCOPIC ENDONASAL TRANSSPHENOIDAL APPROACH FOR SKULL BASE LESION- AVAILABILITY OF MULTILAYERED RECONSTRUCTION METHOD Shigetoshi Yano (Japan)

16:09 P124
		Seong M. Kim (Korea)

16:12 P125

EXPANDED ENDONASAL RESECTION OF SUPRA- AND EXTRA-SELLAR LESIONSRESULTS OF EXTENDED TSA TO ANTERIOR SKULL BASE		TWO-SURGEONS TECHNIQUE FOR INFRATEMPORAL FOSSA TUMOR; SIMULTANEOUS LATERALTRANSZYGOMATIC AND ENDOSCOPIC ENDONASAL APPROACHES WITH TECHNICAL NOTE
Shin Jung (Korea)

16:15 P126
		

Chiung-Chyi Shen (Taiwan)

16:18 P127
		

Jeong-Taik Kwon (Korea)

16:21 P128
		

Sun-Chul Hwang (Korea)

APPLICATION OF ENDOSCOPES IN MINIMALLY INVASIVE NEUROSURGERY
CLINICAL CORRELATION BETWEEN PERITUMORAL EDEMA AND VARIOUS FACTORS IN MENINGIOMA.
MENINGIOMA OPERATIONS IN THE ELDERLY PATIENTS: EFFICIENT WAY TO INTERNAL DECOMPRESSION- 34 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

16:24 P129
		

Peiliang Li (China)

16:27 P130
		

Matthias Kirsch (Germany)

16:30 P131

A 57-patient experience on the surgical strategies of petroclival meningiomas
Retrospective analysis of the post-operative outcome of petroclival meningiomas

		Advantages of the Pterional approach for Olfactory groove and Tuberculum Sellae
Meningiomas
Chul-gu Jung (Korea)

16:33 P132
		

Seong M. Kim (Korea)

16:36 P133
		

Chao Zhang (China)

16:39 P134
		

Mingguang Zhang (China)

16:42 P135
		

Yong Hwy Kim (Korea)

16:45 P136
		

16:48 P137
		

16:51 P138

Meningioma arising from the lateral recess of 4th ventricle
Surgical management for trigeminal schwannoma
LATERAL OR ANTEROLATERAL APPROACH FOR LARGE DUMBBELL-SHAPED CERVICAL NEURINOMA
CLINICAL COURSE OF PIUITARY ADENOMA AFTER APOPLEXY

Efficacy and Safety of Cabergoline as a First Line Treatment for Invasive Giant Male
Prolactinoma
Jeong Hoon Kim (Korea)
COMPARISON OF LATERAL AND SUPERIOR WALLS OF THE PITUITARY FOSSA WITH CLINICAL EMPHASISON PITUITARY ADENOMA EXTENTION: CADAVERIC-ANATOMIC STUDYKaya Aksoy (Turkey)

		

METASTATIC ACTH PRODUCING PITUITARY CARCINOMA (PCA) TREATED WITH TEMOZOLOMIDE(T): CASEREPORT AND REVIEW OF THE LITERATURE
Sarah Taylor (USA)16:54 P139
		

Sun-Chul Hwang (Korea)

16:57 P140

ISOLATED OCULAR PARESIS IN THE PITUITARY ADENOMA: REVIEW OF 4 CASES		The effective treatment of craniopharyngioma using highly conformal
hypofractionated stereotactic irradiation
Moon-Jun Sohn (Korea)

17:03 P141
		

Jeong-Hyun Hwang (Korea)

17:06 P142
		

Min-Su Kim (Korea)

17:09 P143
		

Kang Zheng (China)

17:12 P144

LYMPHOCYTIC HYPOPHYSITIS WITH REFERENCE TO MR IMAGINGCENTRAL NEUROCYTOMA PRESENTING WITH INTRAVENTRICULAR HEMORRHAGE
CLINICAL TREATMENT OF INTRACRANIAL MALIGNANT NERVE SHEATH TUMORS		A RARE TUMOR-LIKE LESION OF PERIPHERAL NERVE SHEATH IN AN UNUSUAL SITE. NEUROMUSCULARCHORISTOMA OF INTRAORBITAL RETROBULBAR CONUS. A CASE REPORT AND LITERATURE REVIEW.
Suat Boyaci (Turkey)

17:15 P145
		

Seung Heon Cha (Korea)

17:18 P146
		

Hiroshi Kanno (Japan)

17:21 P147
		

Fengping Huang (China)

17:24 P148
		

Gang Wu (China)

17:27 P149
		

17:30 P150

CLINICAL EXPERIENCES OF INTRACRANIAL HEMANGIOBLASTOMASURGICAL MANAGEMENT OF CNS HEMANGIOBLASTOMAS IN VON HIPPEL-LINDAU DISEASE
CLINICAL DIAGNOSIS AND TREATMENT OF HYPOTHALAMIC HAMARTOMA IN CHILDREN
CLINICAL DIAGNOSIS AND TREATMENT OF THIRD VENTRICLE CAVERNOUS ANGIOMA

MULTIFOCAL, PROTEINACEOUS CNS DEPOSITS MIMICKING NEOPLASIA: REPORT OF AN UNUSUALCEREBRAL AND CEREBELLAR AMYLOIDOMA WITH LONG LASTING CLINICAL HISTORYPeter Molnar (Hungary)		

PRIMARY BURKITT LYMPHOMA OF CNS IN AN IMMUNOCOMPETENT OLD WOMAN: A RARE CASEREPORT AND REVIEW LITERATURES
Jui-Ming Sun (Taiwan)

17:33 P151
		Young-Cho Koh (Korea)

PRIMARY LEPTOMENINGEAL MELANOMATOSIS IN A 31-YEAR-OLD WOMAN- 35 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

17:36 P152
		

Young-Cho Koh (Korea)

17:39 P153
		

Seong M. Kim (Korea)

17:42 P154
		

Bong Jin Park (Korea)

17:45 P155
		

Bong Jin Park (Korea)

17:48 P156
		

Jarungchai Vatanagul (Philippines)

17:51 P157
		

Ahmet Kahraman (Turkey)

17:54 P158
		

Bong Jin Park (Korea)

17:57 P159
		Tomohiro Kawaguchi (Japan)

18:00 P160
		

18:03 P161

PRIMARY INTRACEREBRAL MALIGNANT FIBROUS HISTIOCYTOMA, CASE REPORTINCIDENTALLY DISCOVERED CLIVAL PSEUDOMENINGOCELE : A CASE REPORTMALIGNANT BRAIN TUMOR IN A PATIENT WITH AIDSGLIOBLASTOMA DEVELOPED IN A CURED PEDIATRIC CNS LEUKEMIAA PATIENT WITH GLIOBLASTOMA MULTIFORME AND A LEFT CERVICAL MASS- A CASE REPORTGLIOBLASTOMA MULTIFORME IN FASCIA LATAINTRAPARENCHYMAL GERMINOMAEARLY DETECTION OF THE VENOUS THROMBOEMBOLISM IN GLIOMA PATIENT

2 CASES OF EXTRADURAL GLIOBLASTOMA MULTIFORME PRESENTING AS TRIGEMINAL NEURALGIA;PATTERNS OF MOLECULAR TARGETS OF INVASIVENESS.
Lawrence Cher (Australia)

		

PONTINE CRYPTOCOCAL GRANULOMA IN A HEALTHY, NON-IMMUNOCOMPROMISED PATIENT-CASE
REPORTKyung Gi Cho (Korea)

18:06 P162
		

Guihuai Wang (China)

18:09 P163
		

Chen Jin-cao (China)

18:12 P164

Surgery for intramedullary spinal tumors
THE RATIONAL NEUROSURGICAL TREATMENT OF PINEAL REGION TUMORS		CONSERVATIVE MANAGEMENT OF PSEUDOMENINGOCEAL FORMATION AFTER POSTERIOR FOSSATUMOR SURGERY IN CHILDREN
Sang-Dae Kim (Korea)

18:15 P165
		

Gerardo D. Legaspi (Philippines)

18:18 P166
		

Keyvan Mostofi (France)

Display P167
only		ATYPICAL RATHKE’S CLEFT CYST WITH CALCIFICATION
Lu-Ting Kuo (Taiwan)

POSTERIOR FOSSA TUMORS WITH HYDROCEPHALUS: OUTCOME OF SURGERY WITHOUT CSF DIVERSIONATYPICAL MENINGIOMA IN FRENCH WEST INDIESMay 14 (Thu)

Room 1lTemozolomide and MGMT
Chairpersons: Yuichi Hirose (Japan)		Tali Siegal (Israel)

08:00 P168
		

08:03 P169

THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND THE
MGMT PROTEIN IN GLIOBLASTOMAS
Tae-Young Jung (Korea)

		

RELEVANCE OF MSP ASSAY FOR THE DETECTION OF MGMT PROMOTER HYPERMETHYLATION IN
GLIOBLASTOMAS
Kazunari Yachi (Japan)

08:06 P170
		

Takao Fukushima (Japan)

08:09 P171
		

08:12 P172
		

Clinical significance of polymorphism of DNA repair gene MGMT in Glioblastomas

IMMUNOHISTOCHEMICAL ASSESSMENT OF O6-METHYLGUANINE DNA METHYLTRANFERASE FORGLIOBLASTOMAS: A REAPPRAISAL
Manabu Natsumeda (Japan)
MGMT METHYLATION STATUS MAY PREDICT SURVIVAL IN ELDERLY PATIENTS WITH NEWLY DIAGNOSEDGLIOBLASTOMA (GBM)
Elizabeth R. Gerstner (USA)- 36 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

08:15 P173		

METHYLATION-SENSITIVE HIGH RESOLUTION MELTING ANALYSIS :A NEW QUANTITATIVE ASSESSMENT
OF MGMT PROMOTER METHYLATION IN GLIOMAS
Jun-ichi Adachi (Japan)

08:18 P174
		

Motoo Nagane (Japan)

08:21 P175
		

08:24 P176
		

08:27 P177
		

08:30 P178

MGMT TESTINGS FOR TEMOZOLOMIDE EFFICACY ON GLIOBLASTOMAA NOVEL AND SPECIFIC INHIBITOR OF MGMT TRANSCRIPTION INCREASES THE SENSITIVITY OF GLIOMACELL LINES TO TEMOZOLOMIDE TREATMENT.
Iris Lavon (Israel)
Mechanism of Thalidomide to enhance the cytotoxicity of Temozolomide in U251-MG
glioma cells in vitro
Xuejun Yang (China)
Neural differentiation markers expression in human glioblastomas may predict their
response to chemotherapy
Igor J. Sulla (Slovak)

		Extended use of temozolomide based on O6-methylguanine-DNAmethyltransferase(MGMT) expression pattern for glioma patients: experience of 17 cases
Zhongping Chen (China)

08:33 P179
		

Veronique Quillien (France)

08:36 O123

Pysosequencing: a good option for MGMT analysis.

		

CDK INHIBITOR BLOCKS DNA REPAIR FOLLOWING G2 CHECKPOINT ACTIVATION IN HUMAN GLIOMACELLS TREATED WITH TEMOZOLOMIDE
Yuichi Hirose (Japan)

08:46 O124
		Congju Zhu (Singapore)

09:00 O125		TEMOZOLOMIDE-INDUCED DIFFERENTIAL EXPRESSION OF DNA REPAIR GENES IN MALIGNANT GLIOMA CELLSMGMT PROMOTER GENE METHYLATION AS DETERMINED WITH MULTIPLEX LIGATION-DEPENDANTPROBE AMPLIFICATION (MLPA) IS PROGNOSTIC FOR SURVIVAL AFTER RADIOTHERAPY BUT NOTPREDICTIVE FOR OUTCOME TO CHEMOTHERAPY IN OLIGODENDROGLIAL TUMORS
Martin van den Bent (Netherlands)lAngiogenesis and Anti-Angiogenesis Therapy
Chairpersons: Turker Kilic (Turkey)
		Roger Stupp (Switzerland)		
Patric Y. Wen (USA)

09:15 P180
		ANGIOGENIC POTENTIAL OF LOW GRADE OLIGODENDROGLIOMAS IS AN IMPORTANT DETERMINANT OFPROGNOSIS
Turker Kilic (Turkey)

09:18 P181
		

Takuhito Narita (USA)09:21 P182
		

09:24 P183
		

09:27 P184
		

09:30 O126
		

09:40 O127		

10:00 O128		IDENTIFICATION OF A NOVEL SMALL MOLECULE HIF-1α TRANSLATION INHIBITOR

PHASE I STUDY OF VANDETANIB, IMATINIB MESYLATE AND HYDROXYUREA FOR RECURRENT
MALIGNANT GLIOMADavid A. Reardon (USA)A PHASE I STUDY OF SUNITINIB PLUS IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT
MALIGNANT GLIOMADavid A. Reardon (USA)A PHASE IB TRIAL OF CEDIRANIB IN ADDITION TO STANDARD TEMOZOLOMIDE AND RADIATIONTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Andrew S. Chi (USA)A PHASE I, OPEN LABEL, MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF
CEDIRANIB [RECENTINTM] IN COMBINATION WITH LOMUSTINE CHEMOTHERAPY FOR PATIENTS WITH
RECURRENT GLIOBLASTOMA
T.T. Batchelor (USA)
MULTIARM COMBINATORIAL STUDY OF SIGNAL TRANSDUCTION MODULATORS USING A SEQUENTIALACCRUAL DESIGN: A REPORT OF THE NORTH AMERICAN BRAIN TUMOR CONSORTIUM (NABTC) 0502
Mark R. Gilbert (USA)PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMAPATIENTS: FINAL STUDY RESULTSDavid A. Reardon (USA)- 37 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

10:10 O129		

BEVACIZUMAB AND NITROSOUREA IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A PHASE II
MULTICENTER ITALIAN STUDY
Roberta Ruda' (Italia)

10:20 O130
		Sith Sathornsumetee (USA)10:30 O131		

BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL

PHENOTYPIC AND PHYSIOLOGIC EFFECTS OF BEVACIZUMAB IN A HIGHLY INFILTRATIVE AND
ANGIOGENIC HUMAN GLIOBLASTOMA MODEL
Simone P. Niclou (Luxembourg)

lLecture from ASNO
Chairperson: Shin-Ichi Miyatake (Japan)

10:55 KN08

Involvement of VEGF-VEGFR System in the Progression of Cancer including Brain Tumors.
Masabumi Shibuya (Japan)

lLunchtime Symposium:
TTFields - A Novel Treatment Modality for Brain Tumor Patients
Sponsored by NovoCure Ltd.
Chairperson: Zvi Ram (Israel)

12:00 Lsy11 INTRODUCTION
Zvi Ram (Israel)		
12:05 Lsy12 Mehanism of action of TTFields
Yoram Palti (Israel)		
12:20 Lsy13 Critical review of TTFields literature		
Zvi Ram (Israel)
12:40 Lsy14 Results of new preclinical studies
		Eilon Kirson (Israel)
12:50 Lsy15 FUTURE CLINICAL TRIALS AND SUMMARY		Roger Stupp (Switzerland)

lChemotherapy, Molecular-Targeted Therapy
Chairperson: Yoshitaka Narita (Japan)

13:00 P185
		THE POTENTIAL BENEFIT OF NEOADJUVANT AND EXTENDED-ADJUVANT TEMOZOLAMIDE WITH THE
STUPP-REGIMEN IN THE TREATMENT OF GLIOBLASTOMA
Ian Brown (UK)

13:03 P186
		

Walter Taal (Netherlands)

13:06 P187
		

13:09 P188
		

13:12 P189
		

13:15 P190
		

13:18 P191
		

13:21 P192
		

13:24 P193
		

DOSE DENSE ONE WEEK ON/ ONE WEEK OFF TEMOZOLOMIDE IN RECURRENT GLIOMA.

CLINICAL TRIAL WITH TEMOZOLOMIDE IN AN ALTERNATING WEEKLY REGIMEN AGAINST RECURRENT
MALIGNANT GLIOMAS-A PRELIMINARY REPORT
Akio Asai (Japan)
SAFETY AND EFFICACY OF NEAR-CONTINUOUS DOSE-DENSE TEMOZOLOMIDE (TEGWONDO) FOR
RECURRENT GLIOMAS
Herwig Strik (Germany)
PHARMACEUTICAL CONTROL OF TEMOZOLOMIDE CHEMOTHERAPY WITH ORIGINAL LEAFLETS AND
ADMINISTRATION HISTORY DATABASE
Sanae Miyano (Japan)
SAFETY AND EFFICACY OF TEMOZOLOMIDE TREATMENT WITH NEWLY DIAGNOSED GLIOBLASTOMA IN
JAPAN. A MULTICENTER PHASE II CLINICAL STUDY
Kazuhiko Sugiyama (Japan)
RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA (GBM) PATIENTS TREATED WITH TEMOZOLOMIDE(TMZ)-RADIOTHERAPY FOLLOWED BY TMZ FOR 2 YEARS OR UNTIL PROGRESSION: SURVIVAL ANALYSIS
Alejandro D Muggeri (Argentine)
PSEUDPROGRESSION OR TUMOR PROGRESSION IN GLIOMAS: WHAT KINDS OF DIAGNOSTIC TOOLSARE MORE RELIABLE?
Kyung Gi Cho (Korea)
HYPOFRACTIONATED HIGH-DOSE IRRADIATION BY IMRT CONCURRENT WITH PROPHYLACTICINTRATHECAL CHEMOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA
Toshihiko Iuchi (Japan)- 38 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

13:27 P194
		

13:30 P195

A PILOT SAFETY TRIAL OF HYPOFRACTIONATED RADIATION THERAPY PLUS CONCOMITANT AND
ADJUVANT TEMOZOLOMIDE FOR ADULTS WITH GLIOBLASTOMA MULTIFORME
Mizuhiko Terasaki (Japan)

		

UPFRONT CHEMOTHERAPY FOR GLIOMAS DELETING 1P AND 19Q FOLLOWED BY SECOND-LOOKREMOVAL AND/OR RADIOTHERAPY AT MAXIMUM RESPONSE
Hikaru Sasaki (Japan)

13:33 P196
		

Jung Ho Han (Korea)

13:36 P197
		

Keiichi Sakai (Japan)

13:39 P198
		

13:42 P199
		

13:45 P200
		

13:48 P201
		

13:51 P202

BENEFIT OF CHEMOTHERPY IN ANAPLASTIC ASTROCYTOMASTHERAPY-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING TREATMENT FOR MALIGNANT GLIOMATENIPOSIDE AND NIMUSTINE REGIMEN FOR MALIGNANT GLIOMAS WITH O6-METHYLGUANINE-DNA
METHYLTRANSFERASE (MGMT) NEGATIVE EXPRESSION: EXPERIENCE OF 18 CASES
Gang Li (China)
SAFETY PROFILE OF CARMUSTINE WAFER TREATMENT IN FIRST LINE TREATMENT OF MALIGNANT
GLIOMA WITH CARMUSTINE IMPLANTS FOLLOWED BY CONCOMITANT RADIOCHEMOTHERAPY
Alf Giese (Germany)
THE GROWTH PATTERN OF RECURRENT GLIOBLASTOMA AFTER GLIADEL(TM) WAFER IMPLANTATION IN
FIRST RECURRENCIES
Dietmar Krex (Germany)
PRE-RADIATION CHEMOTHERAPY WITH ACNU-CDDP IN PATIENTS WITH NEWLY DIAGNOSEDGLIOBLASTOMA: A RETROSPECTIVE ANALYSIS
Jung Ho Han (Korea)

		

A CONCURRENT ASSOCIATION RADIATION THERAPY FOTEMUSTINE FOR NEWLY DIAGNOSEDMALIGNANT GLIOMAS, A PHASE II.
Patrick D Beauchesne (France)

13:54 P203
		

Pournima Navalkele (USA)

13:57 P204
		

Keiichi Kobayashi (Japan)

14:00 P205
		

14:03 P206

TOXICITY PROFILE OF VALPROATE AND ETOPOSIDE METRONOMIC CHEMOTHERAPYCOMBINATION THERAPY WITH CARBOPLATIN AND ETOPOSIDE FOR RECURRENT MALIGNANT GLIOMASPHASE II STUDY OF IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH GLIOBLASTOMA
AT FIRST RELAPSE
Tomokazu Aoki (Japan)

		

PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH BRAINSTEM GLIOMA.
PROTOCOL BC-BT-11
Stanislaw R. Burzynski (USA)14:06 P207
		

Prasanta Banerji (India)

14:09 P208
		

Maciej M. Mrugala (USA)14:12 P209
		

14:15 P210
		

14:18 P211
		

14:21 P212
		

14:27 P213
		

TREATMENT OF PRIMARY MALIGNANT GLIOMAS AND MENINGIOMAS WITH RUTA/CALC PHOS
LEPTOMENINGEAL GLIOMATOSIS IN PATIENTS TREATED WITH BEVACIZUMABRESPONSE TO INTRATHECAL INFUSIONS OF DEPOCYTE IN SECONDARY DIFFUSE LEPTOMENINGEALGLIOMATOSIS. A CASE REPORT.
Patrick D. Beauchesne (France)
NEW THERAPEUTIC APPROACH FOR BRAIN TUMORS: INTRANASAL ADMINISTRATION OF RAS INHIBITOR
MONOTERPENE PERILLYL ALCOHOL.
Clovis Fonseca (Brazil)
CETUXIMAB DOES NOT INFLUENCE SERUM MAGNESIUM HOMEOSTASIS IN PATIENTS WITHGLIOBLASTOMA MULTIFORME TREATED WITH CONCOMITANT RADIOTHERAPY AND TEMOZOLOMIDE
Stefan Rieken (Germany)
A RETROSPECTIVE SINGLE INSTITUTIONAL ANALYSIS OF CILENGITIDE (CGT) AND CHEMOTHERAPY FORHEAVILY PRE-TREATED RECURRENT GLIOBLASTOMA MULTIFORME (GBM).
Mustafa Khasraw (Australia)
CILENGITIDE MODULATES ATTACHMENT AND VIABILITY OF HUMAN GLIOMA CELLS, BUT NOTSENSITIVITY TO IRRADIATION OR TEMOZOLOMIDE IN VITRO
Gabriele Maurer (Germany)- 39 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

14:30 P214METABOLIC FACTORS GOVERN THE CYTOTOXIC POTENTIAL OF EGFR INHIBITION IN HUMAN
MALIGNANT GLIOMA CELLS		Johannes Rieger (Germany)
Chairpersons: Michael Prados (USA)			
		
Roger Stupp (Switzerland)			
14:40 O132		
15:00 O133RESPONSE ASSESSMENT IN NEURO-ONCOLOGYDavid R. Macdonald (Canada)		

CREATION OF A CHEMOTHERAPY SIMULATOR TO PREDICT THE CONCENTRATIONS OF SYSTEMICALLYADMINISTERED CHEMOTHERAPY WITHIN BRAIN TUMOR TISSUE
Stuart A. Grossman (USA)

15:30 O134
		

Terrance G Johns (Australia)

15:40 O135
		

15:50 O136		

16:00 O137
		

16:10 O138		TARGETING OF THE TYROSINE KINASE RECEPTORS EGFRVIII AND C-MET IN GBM

ASSESSMENT OF THE EFFICACY OF ETOPOSIDE AND TEMSIROLIMUS IN AN INTRACRANIAL RODENTMODEL WITH SPECIAL ATTENTION TO THE RELATIONSHIP OF TUMOR AND WHITE CELL P70S6 KINASE
ACTIVITY DURING THERAPY
Jeffrey J. Olson (USA)CDK4/6 SMALL MOLECULE INHIBITOR PD-0332991 DEMONSTRATES ANTI-TUMOR ACTIVITY AGAINSTAN INTRACRANIAL GLIOBLASTOMA XENOGRAFT LACKING p16 FUCNTION
Karine Michaud (USA)RESULTS OF A PHASE IIB STUDY WITH TRABEDERSEN (AP 12009) IN RECURRENT OR REFRACTORY
HIGH-GRADE GLIOMA PATIENTSUlrich Bogdahn (Germany)
PHASE I STUDY OF TERAMEPROCOL IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS: A NABTTCNS CONSORTIUM TRIAL
Stuart A. Grossman (USA)––––––––––––––––––––––––– Break –––––––––––––––––––––––––

Chairpersons: Victor Levin (USA)			
		
Antonio Omuro (USA)

16:40 O139
		

16:50 O140
		

17:10 O141

THE COMBINATION OF TEMOZOLOMIDE AND RTA203, A SELECTIVE H+-ATPASE INHIBITOR, AUGMENT
THE CYTOTOXIC EFFECT ON MALIGNANT GLIOMAS THROUGH BLOCKADE OF AUTOPHAGY
Hiroshi Aoki (Japan)
INTERIM ANALYSIS OF COMBINATION CHEMORADIOTHERAPY BY MEANS OF TEMOZOLOMIDE (TMZ)
AND INTERFERON (IFN) BETA FOR MALIGNANT GLIOMA: MULTICENTER CLINICAL TRIAL (INTEGRASTUDY)
Toshihiko Wakabayashi (Japan)

		

THE KOREAN EXPERIENCES OF CONCURRENT CHEMORADIOTHERAPY WITH TEMOZOLOMIDE FOR THE
NEWLY DIAGNOSED GLIOBLASTOMA: METAANALYSIS OF PROSPECTIVE STUDY OF FOUR CENTERS
Yong-Kil Hong (Korea)

17:20 O142
		

Akihide Kondo (USA)

17:30 O143
		

17:40 O144
		

COMPARISON OF BOLUS AND METRONOMIC CHEMOTHERAPY ON TUMOR CHARACTERISTICSPHASE II TRIAL OF LOW-DOSE CONTINUOUS (METRONOMIC) TREATMENT OF TEMOZOLOMIDE FOR
RECURRENT GLIOBLASTOMA
Jong Hyun Kim (Korea)
A CONTINUOUS SCHEDULE OF TMZ FOR GBM AT FIRST RELAPSE MAY OVERCOME THE THERAPEUTIC
DISADVANTAGE OF NON-METHYLATED MGMT: RESULTS FROM THE PHASE II RESCUE TRIAL
J. Perry (Canada)

lClosing Ceremony
18:00- 40 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPANMay 14 (Thu)

Room 2lPediatric Basic Science I
Sponsored by Pediatric Brain Tumor Foundation

Chairpersons: Annie Huang (Canada)		
Hideo Takeshima (Japan)

08:00 P215
		

08:03 P216
		

08:06 P217

AN EPIGENETIC GENOME-WIDE SCREEN IDENTIFIES THE SFRP FAMILY OF WNT SIGNALING INHIBITORSAS NOVEL TUMOR SUPPRESSOR GENES IN MEDULLOBLASTOMAPaul N. Kongkham (Canada)
SILENCING OF NEURONAL DIFFERENTIATION GENES REVEALED BY PROFILING THE
MEDULLOBLASTOMA EPIMETHYLGENOME
Adrian Dubuc (Canada)		

PEDIATRIC INTRACRANIAL GERM CELL TUMORS OF DIFFERENT PROGNOSIS OUTCOMES AND ETHNICBACKGROUND INHERIT CHARACTERISTIC EMBRYONIC STEM CELL TRAITS AND MICRORNAOME PROFILES
Hsei-Wei Wang (Taiwan)

08:09 P218
		

Kazuo Washiyama (Japan)

08:12 P219
		THE FREQUENT EXPRESSION OF ARF-BP1 IN PRIMARY INTRACRANIAL GERM CELL TUMORSFREQUENT SINGLE NUCLEOTIDE POLYMORPHISM (SNP) OF BCL10 AND ASSOCIATION WITH POOR
PROGNOSIS IN PRIMARY INTRACRANIAL GERM CELL TUMORS
Yutaka Hayashi (Japan)

08:15 P220 EXPRESSION PROFILES OF MICRORNA IN PEDIATRIC MALIGNANT GLIOMAS		
Muh-Lii Liang (Taiwan)
Keynote08:20 KN09 EGFR signaling through an Akt/SREBP1-dependent, rapamycin-resistant pathway
sensitizes glioblastomas to anti-lipogenic therapy
Paul Mischel (USA)		
08:50 O145
		THE MIR-17/92 POLYCISTRON IS AMPLIFIED AND UP-REGULATED IN SONIC HEDGEHOG-DRIVENMEDULLOBLASTOMAS AND INDUCED BY N-MYC IN SONIC HEDGEHOG-TREATED CEREBELLAR NEURALPRECURSORSPaul A. Northcott (Canada)

09:05 O146
		

Yukiko Nakahara (Canada)

EPIGENETIC SILENCING OF KRUPPEL-LIKE FACTOR 4 (KLF4) IN MEDULLOBLASTOMA

lPediatric Neuro-Oncology II
Sponsored by Pediatric Brain Tumor Foundation

Chairpersons: Mark Kieran (USA)		
Yutaka Sawamura (Japan)

Keynote09:30 KN10 MANAGEMENT OF YOUNG CHILDREN NEWLY-DIAGNOSED WITH CENTRAL NERVOUS SYSTEM (CNS)EMBRYONAL TUMORS: 18 YEARS OF THREE SEQUENTIAL IRRADIATION-AVOIDING CHEMOTHERAPYSTUDIES - THE "HEAD START" PROTOCOLS		Jonathan Finlay (USA)09:55 KN11
		The chemotherapeutic management of low grade gliomas
Eric Bouffet (Canada)

10:20 O147		EPENDYMOMA TREATMENT: AN UPDATE
Stergios Zacharoulis (UK)

10:40 O148		MEDULLOBLASTOMA IN INFANTS
Susan Chi (USA)

11:00 O149
		

Sridharan Gururangan (USA)RECURRENT MEDULLOBLASTOMA- RECENT ADVANCES IN TREATMENT

lLunchtime Seminar
Chairperson: Takamitsu Fujimaki (Japan)

Sponsored by Mitsubishi Tanabe Pharma Corporation

12:00 LSe07 HOW NEUROCOGNITIVE OUTCOMES CAN CHANGE CLINICAL TRIAL DESIGN
Elana Farace (USA)		- 41 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

lCognitive Function and Outcome
Chairpersons: Stephen Sands (USA)		
Takaaki Yanagisawa (Japan)

Keynote13:00 KN12 Neuropsychological Functioning and Outcome for Brain Tumor Patients		
Stephen Sands (USA)
13:30 O150
		

13:40 O151
		

13:50 O152		

14:00 O153
		

14:10 O154
		

14:20 O155

MEASURING PERFORMANCE STATUS IN PEDIATRIC BRAIN TUMOR STUDIES EXPERIENCE OF THE HIT-GBM-C PROTOCOL
Kamran Mohiuddin (USA)Development of the Japanese version of Pediatric Quality of Life InventoryTM Brain
Tumor Module
Iori Sato (Japan)
A NEW ASSESSMENT TOOL FOR MEASURING NEUROLOGICAL AND BEHAVIORAL FUNCTION ACROSSLIFESPAN: THE NIH TOOLBOX
Jin-Shei Lai (USA)
Detailed prospective neuropsychological, activity of daily living and endocrine
function assessment in children with craniopharyngioma treated with stereotactic
conformal radiotherapy
Debnarayan Dutta (India)
MANGING CHALLENGING BEHAVIOURS AFTER BRAIN CANCER: A RESOURCE FOR PATIENTS, CARERSAND HEALTH PROVIDERS
Teresa Simpson (Australia)

		

PATIENT FUNCTIONAL STATUS IS STRONGEST CORRELATE OF CHALLENGING BEHAVIOUR AFTER BRAINTUMOUR
Eng-Siew Koh (Australia)

14:30 P221
		

Jin-Shei Lai (USA)14:33 P222
		

14:36 P223

STRESS LEVELS AMONG PARENTS OF CHILDHOOD BRAIN TUMOR SURVIVORSMULTI-TIERED INTERVENTION STUDY FOR PATIENTS, CARERS AND HEALTH PROVIDERS TO ADDRESSCHALLENGING BEHAVIOURS AFTER BRAIN TUMOUR
Eng-Siew Koh (Australia)		

Knowledge and Attitudes On The Diagnosis, Treatment And Prognosis Among Patients
With Brain Tumor And Their Caregivers in a Tertiary HospitaL
Natasha L.Fabiana (Philippines)

14:39 P224
		

Julette F. Batara (Philippines)

Management of Primary Malignant Brain Tumors During Pregnancy

lPediatric Basic Science II
Chairpersons: Catherine Godfraind (Belgium)		
Kazuo Washiyama (Japan)

14:50 O156
		
15:00 O157
		

15:10 O158
		

15:20 O159
		

15:30 O160

MOUSE MODELS OF CNS EMBRYONAL TUMORS

Hiroyuki Momota (Japan)

MULTIPLE RECURRENT GENETIC EVENTS CONVERGE ON CONTROL OF HISTONE LYSINE METHYLATIONIN MEDULLOBLASTOMAPaul A. Northcott (Canada)
CLONAL SELECTION AND PARALLEL EVOLUTION DEFINE THE HIERARCHICAL STRUCTURE OF
METASTATIC MEDULLOBLASTOMA
Xiaochong Wu (Canada)
INTEGRATED GENE EXPRESSION AND COPY-NUMBER ANALYSES IDENTIFY AGGRESSIVE PEDIATRICCENTRAL NERVOUS SYSTEM PRIMITIVE NEURO-ECTODERMAL TUMORS
Annie Huang (Canada)		GENOMIC PROFILING OF INTRACRANIAL GERM CELL TUMORS WITH SINGLE NUCLEOTIDEPOLYMORPHISM ARRAY
Keita Terashima (USA)

15:40 O161
		Catherine Godfraind (Kingdom of Belgium)

PATHWAYS AND GENES ASSOCIATED WITH EPENDYMOMA LOCATION, GRADE AND SUBGROUPS.

- 42 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

16:00 O162		GENETIC PROFILING OF PEDIATRIC NON-EPENDYMAL GLIOMAS ASSOCIATED WITH TEMOZOLOMIDERESISTANCE
Taketo Ezaki (Japan)

16:10 O163		David T.W. Jones (UK)The MAPK pathway is altered in the majority of pilocytic astrocytomas

May 14 (Thu)

Room 3lPoster Presentations: Basic Science
Chairperson: Tomoyuki Koga (Japan)

08:00 P225
		

Wen-Yu Cheng (Taiwan)

08:03 P226
		

Masamichi Takahashi (Japan)

08:06 P227
		

Akihiro Inoue (Japan)

08:09 P228
		

Kiminobu Sugaya (USA)08:12 P229
		

Akio Soeda (USA)08:15 P230
		08:18 P231
		

08:21 P232
		

08:24 P233

Cancer Stem Cells from Glioblastoma Multiforme Patients
Characterization of Cancer Stem-like Cells Derived from Human Glioblastomas
Characterization of cancer stem cells in human glioblastomas
CHARACTERIZATION OF TUMOR STEM CELLS ISOLATED FORM HUMAN GLIOBLASTOMA MULTIFORMESTAT3 SERINE727 ACTIVATION IN GLIOMA CANCER STEM CELLSENHANCEMENT OF STEM-LIKE GLIOMA NEUROSPHERE RADIORESPONSE BY GEFITINIB: BY INCREASEDDNA DAMAGE AND REDUCED DNA REPAIR CAPACITY
Khong Bee Kang (Singapore)
INHIBITION OF TUMOR GROWTH AND ANGIOGENESIS BY TARGETING CXCL12/CXCR4 AXIS IN STEM
CELL-LIKE GLIOMA CELLS
Xiu-wu Bian (China)
Cultivation and identification of the cells from central nervous systemhemangioblastomas and its stem cells origin
Rong Xie (China)

		Screen and identify the critical proteins of central nervous systemhemangioblastoma tumor cells using on-line capillary 2D-HPLC combined with LTQOrbitrap MS
Rong Xie (China)

08:30 P234
		You P. You (China)

08:33 P235
		

Tatsuya Takezaki (Japan)

08:36 P236
		

08:39 P237
		

08:42 P238

Notch1 induces more expression of DLL1 in U251MG glioma cell line
HEDGEHOG PATHWAY AND GLIOMAGENESIS

The functional analysis of a novel KDR (VEGFR II)-PDGFR-alpha fusion gene inglioblastoma: From discovery to clinical application
Tatsuya Ozawa (USA)
Isolation and Characterization of an N-Linked Oligosaccharide That Is Increased in
Glioblastoma Tissue and Cell Line.
Ryuya Yamanaka (Japan)		Inhibition of glioma proliferation by modified p53 protein fused with proteintransduction domains
Hiroyuki Michiue (Japan)

08:45 P239
		

Stine S. Jensen (Denmark)

08:48 P240

EXPRESSION OF THE LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN-1 (LAMP-1) IN ASTROCYTOMAS		EVALUATION OF ELK-1 ACTIVATION BY PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY IN
GLIOBLASTOMA
Melike Mut (Turkey)

08:51 P241
		

Sonali Patil (USA)ANTINEOPLASTONS INHIBIT MCM COMPLEX IN GLIOBLASTOMA CELLS- 43 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

08:54 P242
		

08:57 P243
		

09:00 P244
		

09:03 P245
		

09:06 P246

ENHANCED EXPRESSION OF NADPH OXIDASE NOX4 IN HUMAN GLIOMAS AND ITS ROLES IN CELLPROLIFERATION AND SURVIVAL
Tadahisa Shono (Japan)
EXPRESSION PATTERN OF EGFRS, INTEGRINS, AND RELATED MOLECULES IN HUMAN GLIOBLASTOMAVERSUS INTRACEREBRAL LUNG ADENOCARCINOMA METASTASIS
Almos Klekner (Hungary)
INHIBITION OF LRIG3 GENE EXPRESSION VIA RNA INTERFERENCE MODULATES THE PROLIFERATION,
CELL CYCLE, CELL APOPTOSIS, ADHESION AND INVASION OF GLIOBLASTOMA CELL
Dongsheng Guo (China)
PROMYELOCYTIC LEUKEMIA PROTEIN INDUCES APOPTOSIS BY THE REPRESSION OF NFκB ACTIVATIONIN GLIOBLASTOMA CELLS.
Kazuhito Matsuzaki (Japan)		

The cellular oncogene ets-1 counteracts p53 tumour suppressor activity by affecting
the level of p53 protein.
Ella L. Kim (Germany)

09:09 P247
		

Thomas Asklund (Spain)

09:12 P248
		

09:15 P249
		

09:18 P250
		

09:21 P251

Cooperative cytotoxicity by HDAC inhibitors and RTKIs: induction of Cx43 in GBM cells

A MDR1 (ABCB1) GENE SINGLE NUCLEOTIDE POLYMORPHISM PREDICTS OUTCOME OFTEMOZOLOMIDE TREATMENT IN GLIOBLASTOMA PATIENTS
Dietmar Krex (Germany)
Diversity of DNA damage response of astrocytes and glioblastoma cell lines withvarious p53 status to treatment with etoposide and temozolomide
Yuichi Sato (Japan)
The decreased expression of GANP is associated with chromosomal instability inmalignant gliomas
Kazutaka Ohta (Japan)		

ELK4 NEUTRALISATION SENSITISES HIGH GRADE GLIOMA TO APOPTOSIS THROUGH DOWNREGULATION OF THE ANTI-APOPTOTIC PROTEIN MCL-1
Brett W Stringer (Australia)

09:24 P252
		

Hiroshi Nawashiro (Japan)

09:27 P253
		

Gulsah Cecener (Turkey)

xCT as a potential molecular target in glioblastoma multiforme
A novel MMAC/PTEN gene mutation in a GBM patient––––––––––––––––––––––––– Break –––––––––––––––––––––––––

Chairperson: Kenji Wakiya (Japan)

09:40 P254
		

09:43 P255
		

09:46 P256
		
09:49 P257
		

09:52 P258
		

09:55 P259

ATTRACTION OF HEMATOPOIETIC PROGENITOR CELLS BY EXPERIMENTAL GLIOMAS IN VIVO: TOWARDSA CELL-BASED THERAPY FOR MALIGNANT GLIOMAS?
Ghazaleh Tabatabai (Germany)
OLIGODENDROGLIOMAS WITH LOH 1P/19Q: IDENTIFYING GENES ASSOCIATED WITH THERAPEUTICSENSITIVITY
Cathy A Payne (Australia)
ASSOCIATION OF 7Q34 COPY NUMBER GAINS AND KIAA1549-BRAF GENE FUSIONS WITH JUVENILE
PILOCYTIC ASTROCYTOMA
J.Graeme Hodgson (USA)IDH-1 mutations are frequent in low grade glioma and do not correlate with outcome
to temozolomide chemotherapy
Erik-Jan Dubbink (Netherlands)
PPAR-γactivators: Off-target against TGF-β mediated glioma cell migration and brain
invasion
Sebastian M. Seufert (Germany)		Tight junction protein Occludin in human brain tumors: Radiological correlation andprognostic implication on the survival
Choong-Hyun Kim (Korea)

09:58 P260
		Charlotte Aaberg-Jessen (Denmark)

Expression of the TIMP-1 interacting cell surface protein CD63 in astrocytomas- 44 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

10:01 P261
		

10:04 P262

Molecular Variations in Tumor-Host Interactions between Invasive and Angiogenic
Phenotype in High Grade Gliomas
Uros Rajcevic (Luxembourg)		

MULTI-MODAL IMAGING OF ACUTE AND CHRONIC UP-REGULATION OF HYPOXIA-INDUCIBLE FACTOR-1(HIF-1) IN TUMORS
Tadashi Miyagawa (Japan)

10:07 P263
		

Keisuke Miyake (Japan)

10:10 P264
		

10:13 P265
		

10:16 P266

Relationship between ABC transporter proteins and vasculogenesis in glioblastomas

Histone deacetylase inhibitor, valproic acid inhibits glioma angiogenesis in vitro and invivo in the brain
Satoru Osuka (Japan)
The p14ARF tumor suppressor inhibits Glioma-Induced Angiogenesis by a Novel Mdm2/
Sp1/Timp3 Signaling Axis
Erwin G Van Meir (USA)		

Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells tocytotoxic T-lymphocytes by down-regulating ICAM-1 expression
Ryo Ueda (USA)

10:19 P267
Cancelled

Hypoxia-induced Stat3 activity contributes the HIF-1, VEGF, MMP2 and TWIST expression inhuman glioblastoma, which induce angiogenesis and cell migration.

10:22 P268
		NOVEL MONOCLONAL ANTIBODY 13R2.C3 AGAINST IINTERLEUKIN 13 RECEPTOR ALPHA-2 REVEALS A
SPECIFIC AND MORE WIDE-SPREAD EXPRESSION OF THE RECEPTOR IN VARIOUS BRAIN TUMORS
Waldemar Debinski (USA)10:25 P269
		

Atsuo Yoshino (Japan)

10:28 P270

Synergistic effect of human IFN-BETA and TMZ on malignant glioma cell lines		

The role of chemokine SDF-1/CXCR4/CXCR7 for glioblastoma angiogenesis andglioblastoma derived endothelial cells
Shingo Takano (Japan)

10:31 P271
		James Miller (Germany)

10:34 P272
		

10:37 P273

Soluble CD70 Confers an Immune-Mediated Survival Advantage in Experimental Glioblastoma

Aberrant Hypermethylation of CpG islands Profile of Cell Cycle Regulatory Genes in
Malignant Astrocytomas
Takashi Ohta (Japan)

		An in vitro study of selected synthetic chalcone analogues activity against Ben-Men-1
meningioma cell line
Igor Sulla (Slovak)

1040 P274
		

Rong Xie (China)

10:43 P275
		

Daisuke Muta (Japan)

10:55 P276
		

Yoshihiro Numa (Japan)

10:58 P277
		

Zhongping Chen (China)

1101

P278

New CCM1 gene mutations in Chinese sporadic intracranial cavernous angioma patients
The functional role of eIF4E in primary central nervous system lymphoma

Is it Total removal of glioblastoma possible? - tumor cell infiltration from autopsy brain
Clinical significance of vasculogenic mimicry in human gliomas		Validation of prognostic and therapeutic worth of molecular markers by routine
tools in diagnostic and clinical neuropathology: a study of 193 glioblastomas.
Bianca Pollo (Italia)

11:04 P279
		

Horacio Martinetto (Argentine)

11:07 P280
		

11:10 P281
		

OLIGODENDROGLIAL TUMOR CLASSIFICATION: PHENOTYPE VS GENETIC SIGNATUREHISTOLOGIC ANAPLASIA IN SPORADIC AND NF1-ASSOCIATED PILOCYTIC ASTROCYTOMAS PREDICTSUNFAVORABLE BEHAVIOR
Fausto J. Rodriguez (USA)APPLICATION OF A CYTOGENETC PROGRESSION SCORE (GPS), TUMOR LOCATION AND GENETICPROGRESSION IN MENINGIOMAS: HACETTEPE EXPERIENCE
Melike Mut (Turkey)- 45 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

11:13 P282
		

11:16 P283
		

11:19 P284
		

11:22 P285

Targeting the tumor stroma a novel therapeutic strategy based on separate analysisof the malignant and stromal cell compartments in brain tumors
Jian Wang (Norway)
Therapeutic efficacy of a polymeric micellar doxorubicin infused by convectionenhanced delivery against intracranial 9L brain tumor models
Yoji Yamashita (Japan)
Label-free Differentiation of individual human glioma cells by optical FTIR
spectroscopic imaging
Matthias Kirsch (Germany)		Application of multiple-stage tandem imaging mass spectrometry to the evaluation oflipids in a rat brain C6 glioma model
Shinichiro Koizumi (Japan)

11:25 P286
		

Matthias Kirsch (Germany)

11:28 P287

Spectroscopic imaging of cerebral micrometastases in a murine model		Significance of NMR based metabolomics (metabolome) for the prediction of malignant
type meningioma using the analysis of water and lipid-soluble metabolites
Hiroshi Takahashi (Japan)

11:31 P288
		Jae ho Kim (Korea)

11:34 P289
Cancelled
11:37 P290

Role of Proteomic study of CSF as a diagnostic tool in the patients with meningiomas
IL-6 IN MENINGIOMA; EXPRESSION IS CORRELATED WITH PERITUMORAL EDEMA AND VEGF

		

Antitumor effect of humanized anti-IL-6 receptor antibody (tocilizumab) on glioma cellproliferation
Mareina Kudo (Japan)

11:40 P291
		

Ann-Shung Lieu (Taiwan)

11:43 P292
		Yi Lin (China)

11:46 P293
		

Dae-Hee Lee (USA)

Display P294
only		

Lu-Ting Kuo (Taiwan)

The Plasma Concentration of ET-1 in the Brain Tumors
Plasma Ig E levels correlate with diagnosis and response to therapy in glioma patients
DELETION OF PTEN IN CLIVAL CHORDOMAS
Promoter methylation profiles of six tumor-related genes in various brain tumorslLunchtime Symposium
Chairperson: Chen-Nen Chang (Taiwan)

12:00 LSy16 HIGH-PRECISION RADIOTHERAPY FOR CNS TUMORS USING NEW HIGH-TECH MACHINES		
Yuta Shibamoto (Japan)lRadiation Oncology
Chairpersons: Rakesh Jalali (India)
		Normand Laperriere (Canada)

13:00 O164
		

13:10 O165
		

13:20 O166
		

13:30 O167
		

13:40 O168		PATIENT-SPECIFIC VIRTUAL CONTROLS CAN BE USED TO SIMULATE AND PREDICT RESPONSE TORADIATION THERAPY IN INDIVIDUAL GLIOBLASTOMA PATIENTS
Kristin R Swanson (USA)CAN WHOLE BRAIN IRRADIATION (WBI) REALLY IMPROVE NEUROLOGICAL STATUS AND QUALITY OF LIFE
OF PATIENTS WITH BRAIN METASTASES (BM)? A PROSPECTIVE MULTICENTER ANALYSIS OF THE
BARCELONA GLIOMA GROUP. FINAL RESULTS
Salvador Villa (Israel)
INTENSITY MODULATED RADIATION THERAPY FOR CRANIOSPINAL IRRADIATION USING HELICALTOMOTHERAPY: FROM PLANNING TO DELIVERY
Tejpal Gupta (India)
Age and radiotherapy doses to left temporal lobe predict neurocognitive outcomes inyoung patients with benign and low grade brain tumours: data from a prospective
trial of stereotactic conformal radiotherapy
Rakesh Jalali (India)
Carbon ion radiation therapy for paediatic patients and young adults treated fortumors of the skull base
Stephanie E Combs (Germany)- 46 -

May 11-14, 2009 PACIFICO YOKOHAMA, JAPAN

14:00 O169
		

Shin-Ichi Miyatake (Japan)

14:10 O170
		

Shin-Ichi Miyatake (Japan)

14:20 P295
		

14:23 P296

Pseudoprogression in boron neutron capture therapy
Diagnosis and treatment of radiation necrosis in the brain

SHORT COURSE OF RADIOTHERAPY AND CONCOMITANT TEMOZOLOMIDE IN PATIENTS AFFECTED WITHGLIOBLASTOMA WITH V-VI PROGNOSTIC CLASSES. A PILOT STUDY
Salvador Villa (Spain)		Assessment of 11C-methionine PET Changes for Monitoring Therapeutic Response
Following Simultaneous Integrated Boost Technique for Glioblastoma Multiforme
Kazuhiro Miwa (Japan)

14:26 P297
Cancelled

RECURRENCE PATTERN AFTER [(18)F]FLUOROETHYLTYROSINE- POSITRON EMISSION TOMOGRAPHYGUIDED RADIOTHERAPY FOR HIGH-GRADE GLIOMA.

14:29 P298
		

Rhabdomyosarcoma as a late complication of Stereotactic Radiotherapy in the patientwith Neurofibromatosis Type 2
Dusica Babovic-Vuksanovic (USA)14:32 P299
		

Alexander Lossos (Israel)

14:35 P300
		Katarzyna Elandt (Austria)

14:38 P301
		

14:41 P302

RADIATION-INDUCED CEREBRAL CAVERNOUS HEMANGIOMAS IN ADULTS.
Hematotoxicity of craniospinal irradiation in adult patients

Inspection about recurrence and progressing dementia after WBRT to metastatic brain
tumor - Problem presentation against WBRT Akio Asai (Japan)

		Novalis Shaped Beam Radiosurgery for cranial and spinal tumors: 8 years of experiencein Korea
Hae-Won Gu (Korea)

14:44 P303				ULTRAFRACTIONATED RADIATION THERAPY (3 DOSES PER DAY) FOR INOPERABLE GLIOBLASTOMAS.
A NEW AND PROMISING REGIMEN.
Patrick D Beauchesne (France)

14:47 P304
		

Felix Bokstein (Israel)

14:50 P305
		

Da-Tong Ju (Taiwan)

14:53 P306
		

14:56 P307
		

14:59 P308
		

15:02 P309

STEREOTACTIC RADIOSURGERY (SRS) IN RECURRENT HIGH-GRADE GLIOMA
TREATED WITH CYBERKNIFE STEREOTACTIC RADIOSURGERY: TWO CYBERKNIFE CENTERS EXPERIENCE

Peritumoral edema after Cyberknife radiosurgery for meningioma: Report of twocases and Review of literature.
Cheng-Ta Hsieh (Taiwan)
Preliminary results of initially trated patients-FEASIBILITY OF APPLYING THE SYNERGY-S
SYSTEM FOR STEREOTACTIC IRRADIATION SPINAL TUMORS
Andrew A. Kanner (Israel)
DOSE-VOLUME ANALYSIS OF WHOLE VENTRICULAR IRRADIATION BY PROTON BEAM COMPARING WITH
INTENSITY MODULATED RADIOTHERAPY AND STANDARD PHOTON THERAPY
Hiroshi Fuji (Japan)		

IN VIVO BIODISTRIBUTION OF BORON AFTER INTRAVENOUS 4-DIHYDROXYBORYLPHENYLALANINEFRUCTOSE (BPA-F) INFUSION IN MENINGIOMA AND SCHWANNOMA: A FEASIBILITY STUDY FOR BORON
NEUTRON CAPTURE THERAPY(BNCT)
Merja E Kallio (Finland)

15:05 P310
		

Shinji Kawabata (Japan)

15:08 P311
		

Arturas Sitkauskas (Republic of Lithuania)

Clinical Results of Modified Boron Neutron Capture Therapy for Malignant Glioma
BRAIN TUMORS BRACHYTHERAPY BY USING RIGID IR192 CATHETER

lPrimary Central Nervous System Lymphoma
Sponsored by Toray Medical Co., Ltd.

Chairpersons: Norio Arita (Japan)
		Brian Patrick O’Neill (USA)Keynote15:20 KN13 Primary Central Nervous System Lymphoma
Antonio Omuro (USA)		- 47 -

The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with
The 6th Meeting of the Asian Society for Neuro-Oncology (ASNO)

15:50 O171
		

16:00 O172
		

16:10 O173
		

16:30 O174
		

16:40 P312
		

16:43 P313
		

16:46 P314
		

16:49 P315
		

16:52 P316

BRIEF REPORT: ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ACGH) CONFIRMS FLUORESCENT IN
SITU HYBRIDIZATION (FISH) 6Q DELETION IN POOR-PROGNOSIS DIFFUSE LARGE B-CELL, CD20
POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL).
Brian Patrick O’Neill (USA)Primary central nervous system lymphomas derive from B-cell in transition stage
from germinal center B-cell to post germinal center B-cell.
Manabu Kinoshita (Japan)
NEUROLYMPHOMATOSIS (NL)IN HEMATOLOGIC MALIGNANCIES:AN INTERNATIONAL PRIMARY CNSLYMPHOMA COLLABORATIVE GROUP REPORT.
Sigal Grisariu (Israel)
Salvage chemotherapy with temozolomide in refractory or relapsed primary central
nervous system lymphoma
Keishi Makino (Japan)
IMAGING FEATURES IN PARENCHYMAL LYMPHOMATOUS MASSES IN BRAIN: PRIMARY CNS LYMPHOMAOR SYSTEMIC INVOLVEMENT OF THE BRAIN?
Melike Mut (Turkey)
Long-term Survival in Primary CNS Lymphoma Treated by High-dose Methotrexate
Monochemotherapy: role of STAT6 Activation as prognostic determinant
Seung-Ho Yang (Korea)
Treatment for primary CNS lymphoma with high-dose MTX and salvage therapy with
ESHAP
Hiroshi Kanno (Japan)
Treatment of Primary Central Nervous System Lymphoma with Temozolomide,
Vincristine, Doxorubicin, Prednisone and Rituximab
Yi Lin (China)		Intravenous rituximab combined with temozolomide as a second line therapy for CD20
positive primary central nervous system malignant lymphoma
Akira Matsuno (Japan)

16:55 P317
		

Tomotsugu Ichikawa (Japan)

16:59 P318
		

Maintenance therapy using rituximab for primary central nervous system lymphoma

Diagnosis and Management of Spinal Extradural Non-Hodgkin Lymphoma:Analysis ofThree Cases and Review of the Literature
Chi-tun Tang (Taiwan)- 48 -